1	Monday, 20 February 2012
2	(10.00 am)
3	(Delay in proceedings)
4	(10.10 am)
5	THE CHAIRMAN: First of all, ladies and gentlemen, thank you
6	for coming today. Everyone is welcome to the opening of
7	this Inquiry. As you know, from a note which was issued
8	by me on Friday, there have been developments and they
9	will be the subject of debate later on today. But
10	before we get into that area, I now want to invite
11	Ms Anyadike-Danes, senior counsel to the Inquiry, to
12	give her opening address.
13	After she has completed that, any other party who
14	has signalled an intention to make an opening submission
15	will do so and, after the opening submissions are
16	complete, we will then turn to deal with the immediate
17	issue, which was the subject of Friday's note.
18	Ms Anyadike-Danes?
19	Opening by MS ANYADIKE-DANES
20	MS ANYADIKE-DANES: Thank you very much, Mr Chairman.
21	I wonder if we could just check if the IT is working as
22	I see that screen doesn't seem to be. (Pause).
23	First, may I introduce myself. I am
24	Monye Anyadike-Danes, senior counsel to the Inquiry.
25	I should like to start by saying that the whole of the

whole legal team is very much aware that we are dealing here with the deaths of young children, some of whom were very young and some were the only child or the only daughter. On behalf of us all, I should like to express our condolences to the families of the children.

6 However, this Inquiry is not just about the deaths 7 in hospital of Adam Strain, Claire Roberts, Lucy 8 Crawford, Raychel Ferguson and Conor Mitchell, nor is it 9 just about the role of hyponatraemia and the intravenous 10 administration of what has become known as "Solution No. 18" played in their deaths or any other mechanism that 11 12 might have led to the gross cerebral oedema and coning 13 although it involves all of those matters -- but arguably the legacy questions which arise from them 14 15 are: how should lessons be learned from the deaths of 16 children in hospital so as to reduce the incidence of such deaths recurring? Who has the responsibility to 17 ensure that those lessons are learned and practices 18 changed accordingly? 19

20 Nevertheless, the deaths of Adam, Lucy and Raychel 21 were instrumental to the establishment of this Inquiry 22 and the deaths of Claire and Conor are also crucial for 23 the issues the Inquiry is to consider and may well be so 24 for the recommendations that you, Mr. Chairman, will make 25 in due course.

I shall therefore start by briefly saying something 1 2 about each of the children. What I say now is not intended to be an opening into the issues concerning the 3 4 cases of the individual children; there will be separate openings for the cases of Adam, Claire and Raychel, 5 6 which will include Lucy's death and its aftermath, and 7 for Conor. I also need to say that the Inquiry's 8 investigations are continuing into some of the clinical 9 issues in Adam's case and clinical issues into the cases 10 of the other children. Furthermore, the investigation into the governance issues for all of the children's 11 12 cases and the position of the department is still 13 continuing. Accordingly, what I can say in this general opening will, to some extent, be constrained by the need 14 15 to ensure that those investigations are not compromised.

16 So then if I start with the children and start with Adam, who is first in time. Adam Strain was born on 17 4 August 1991 and he was an only child. He was born 18 with cystic, dysplastic kidneys with associated problems 19 20 with the drainage of his kidneys relating to obstruction 21 and vesico ureteric reflux. There is a glossary of 22 medical terms and we have prepared that and it has been 23 compiled for Adam's case and there will be one for the cases of each of the other children. I'm going to call 24 25 that up now. The actual glossary is at

reference 303-002-011, but I'd like to call up the
 particular part of that glossary that deals with Adam's
 diagnosis. If I can call up 303-002-022.

And then we can see there the term "dysplastic 4 5 kidneys". So far as we have been able to do it, all the 6 medical terminology that has been used, whether it's in 7 expert reports or in witness statements, has been 8 reduced to this glossary. This is really in aid of you 9 and us, for that matter. And if we go to the other part 10 of his diagnosis -- and if I call up now 303-002-047, you can see there the vesicoureteral reflux. 11 There you 12 see it.

13 In general, therefore, unless it is of particular significance to a matter in issue, I shall not provide 14 15 a definition of medical terms and conditions. However, 16 for present purposes, Adam's condition basically meant that his kidneys were abnormally formed before birth, 17 causing them to be small and to function poorly and 18 improperly. But despite his medical problems, his 19 20 mother describes Adam as a very happy, content child who 21 was full of energy and bore bravely the very many 22 procedures that he had to undergo. He was his mother's 23 only child and she has provided a handbook, "Adam Strain and the Hyponatraemia Public Inquiry", as a tribute to 24 him. I should say that all these documents that I refer 25

to I have provided a reference, and when you get the written opening or you look at it online, you'll be able to see all the documents that I have referred to.

Adam was placed on the kidney transplant register on 4 5 24 November 1994. On 26 November 1995, there was an 6 offer of a kidney for Adam and he was admitted to the 7 Royal Belfast Hospital For Sick Children that evening. 8 Adam's kidney transplant surgery was commenced the 9 following morning. His consultant nephrologist was Dr 10 Maurice Savage who was professor of paediatrics at Queen's University Belfast. He was not available for 11 12 the entirety of the surgery and cover was provided by 13 another consultant nephrologist, Dr Mary O'Connor. The transplant surgeon was Mr Patrick Keane and he was 14 15 assisted by Mr Stephen Brown, who was also at the 16 Belfast City Hospital.

17 The anaesthetist was Dr Robert Taylor and he was 18 assisted by Dr Terence Montague, who has since left the 19 Royal Belfast Hospital For Sick Children. Dr Montague 20 did not remain for the entirety of the surgery. There 21 is an issue to be addressed in the oral hearing in 22 Adam's case as to whether or not Dr Montague was 23 replaced and, if so, by whom.

A comprehensive list of persons has been provided in Adam's case, which shows the title, grade and role of

all those involved in Adam's clinical case, and I'm just 1 2 going to pull up one part of the beginning of it to show you how it works. That's at reference 303-001-001. If 3 4 you see that now, you will see that there is a reference to the witness number down at the immediate left and 5 6 then there is the name of the witness, the position they 7 hold, a description of their role and then, towards the 8 right-hand side, there are columns which indicate 9 whether they've made statements previously and, if so, 10 when they made them and for whom they made them. If I just show one by way of example. Can we look at 11 12 Dr Alison Armour there?

13 You see that she's witness 12. You see what her 14 position was. And you see where she is now. She's now 15 consultant pathologist, Royal Preston Hospital. You can 16 see her role, she carried out the post-mortem examination of Adam and reported the cause of his death. 17 If you go back again to the main part of that, if you're 18 still following along that line, you'll see she provided 19 20 a deposition to the coroner, she also made a statement 21 to the PSNI. She has made two statements for the 22 Inquiry and she is a proposed witness.

23 That list of persons works its way through in that 24 form with different categories, whether they are main 25 medical clinicians -- that means that they were involved

in the 26th to 29th -- or there were other medical 1 2 clinicians -- and that means they were involved at some time with Adam prior to that date -- whether they are 3 experts, if so who for, and so on. It is there for you 4 to see and is intended to assist you as you hear the 5 6 names called or work your way through them to know who 7 these people are and what role we think they may have had. 8

9 A similar list will be provided for each of the 10 other children's cases as well as for the governance issues. There's a companion document which has been 11 12 compiled, providing the nomenclature and grading of 13 doctors, together with a similar document for nurses. We can look at that quickly. The one for doctors is 14 15 referenced at 303-002-048. There you see the purpose of 16 this is really to help you a little bit with the nomenclature for the various doctors and their grading 17 and, as that happened over time -- and I have pulled up 18 the first page there -- but it goes on through to show 19 20 all the positions. If we call up the equivalent for nurses, 303-003-051, there's the equivalent for nurses. 21 22 Unless it is of particular relevance to the issues, 23 I will not propose to deal with grading or training of any particular clinician. Obviously, I will give their 24 position, but I will leave it for the nomenclature to 25

assist you in what that actually means. Obviously, if
 something turns on it, then we will address it.

An important issue for the Inquiry in Adam's case, 3 as with all the cases, is the nature of the intravenous 4 fluids he received. Adam and several of the other 5 6 children were administered an intravenous solution of 7 0.18 per cent sodium chloride in 4 per cent dextrose, 8 which is known colloquially as Solution No. 18. Over 9 the course of his surgery, from the initial preparation 10 for anaesthesia to the end of his surgery, Adam received 1,500 ml of that solution, along with approximately 11 12 1,500 ml of blood and other solutions. The type, volume 13 and rate of administration of the intravenous fluids are issues for the Inquiry in all the cases. 14

15 Unfortunately, Adam did not recover from his 16 transplant surgery and he died on 28 November 1995. An autopsy was carried out on 29 November 1995 by Dr 17 Alison Armour, who was then a senior registrar in 18 forensic science at the State Pathologist Department. 19 20 The extent to which she sought and received specialist 21 assistance with it from Dr Mirakhur, who was then the 22 consultant neuropathologist at the Royal, and Dr Denis 23 O'Hara, who was a consultant paediatric pathologist, now deceased, or Dr Bharucha, then a consultant 24 haematologist at the Royal, and the extent to which any 25

of that input is reflected in her report and autopsy are
 all matters to be addressed in the oral hearing in
 Adam's case.

Also on 29 November 1995, Adam's death was referred 4 to Mr John Leckey, then the Coroner for Greater Belfast. 5 6 He now holds the position of Senior Coroner for 7 Northern Ireland. Mr Leckey was also the coroner for the inquests into the deaths of all the other children. 8 9 An inquest was conducted into Adam's death on 18 June 10 and 21 June 1996 by the coroner and he engaged a number of experts to assist him, Dr John Alexander, firstly. 11 12 He was consultant anaesthetist at Belfast City Hospital; 13 he's now retired. He concluded that:

14 "The complex metabolic and fluid requirements of 15 this child having major surgery led to the 16 administration of a large volume of hypotonic saline, 17 which produced a dilutional hyponatraemia and subsequent 18 cerebral oedema."

He also expressed the view that hyponatraemia and subsequent cerebral oedema -- and the view that the problem could not be recognised until the surgery was completed.

23 The coroner also had Dr Edward Sumner, who was then 24 the consultant paediatric anaesthetist at Great Ormond 25 Street. He concluded:

"On the balance of probabilities, Adam's gross 1 2 cerebral oedema was caused by the acute onset of hyponatraemia from the excess administration of fluids 3 4 containing only very small amounts of sodium. This 5 state was exacerbated by the blood loss and possibly by 6 the overnight dialysis. A further exacerbating cause 7 may have been the obstruction to the venous drainage of 8 the head. If drugs such as antibiotics were 9 administered through a venous line in a 10 partially-obstructed neck vein then it is possible that they could cause some cerebral damage as well." 11 12 And he went on to comment in his evidence to 13 the coroner: "I believe that without the venous drainage problem, 14 15 Adam may have survived, provided his serum sodium level 16 did not drop below 123." Professor Jeremy Berry, another expert who was 17 available to the coroner, he was from the department of 18 paediatric pathology at St Michael's Hospital, Bristol. 19 He had the benefit of histological slides and concluded 20 21 that: 22 "Oedema was not conspicuous in the lungs. Curious 23 foci of clear cell change in heptocytes scattered throughout the liver substance [the significance of 24 which he did not know] and that the transplant kidney

10

was infarcted [dead]. The extent of the change
 suggested that this occurred at or before the time of
 transplantation."

Dr Sumner was also appointed by the coroner as an 4 expert in the inquest into the deaths of all the other 5 6 children, save for Claire, whose inquest was held in 7 2006. Accordingly, the coroner had the benefit of Dr Sumner's view of the relationship between the 8 9 administration of excessive amounts of low sodium 10 fluids, hyponatraemia, and gross cerebral oedema in the cases of four of the children, all with different 11 presentations, and spanning a period of eight years. 12 13 The significance, if any, of that consistency of view is a matter being considered by the Inquiry. 14

15 The verdict on inquest -- and we can pull that up 16 for Adam at document 011-016-114 -- there you see it. 17 That identified cerebral oedema as the cause of 18 Adam's death with dilutional hyponatraemia and impaired 19 cerebral perfusion as contributory factors. And

21 caused by the acute onset of hyponatraemia from the e xcess

the coroner found that the onset of cerebral oedema was

administration of fluids containing only very small amounts of sodium and

this was exacerbated by blood loss and possibly the overnight dialysis and the obstruction of the venous drainage from the head. The inquest verdict is recorded on Adam's death certificate as the cause of his death.

20

1 The effect of the fluids that were administered to 2 Adam, their content, infusion rate and total amount will 3 be addressed in the oral hearing in to his case. So too 4 is the extent to which there was any obstruction of the 5 venous drainage from Adam's head, and if there was, how 6 it occurred and what effect it had.

7 In the course of giving evidence to the inquest, 8 Dr Taylor produced a draft statement on future practice, 9 the contents of which were reported in the media. It 10 seems that that statement was the product of all the consultant paediatric anaesthetists at the time, namely 11 12 Dr Taylor, Dr Peter Crean who was a consultant in 13 paediatric anaesthesia in intensive care, Dr Seamus 14 McKaigue, he was a consultant paediatric anaesthetist, 15 as well as being approved by Dr Joseph Gaston. He was 16 consultant anaesthetist and clinical director for anaesthesia, theatres and intensive care. The coroner 17 has expressed a view that he had assumed that the 18 Belfast Hospital For Sick Children would have circulated 19 20 other hospitals in Northern Ireland with details of the 21 evidence given at the inquest and possibly some best 22 practice guidelines.

23 The reasons why he might have formed that view
24 precisely what happened to the statement, and more
25 generally what happened as a result of Adam's death, are

all matters to be investigated during the oral hearing
 in Adam's case.

If I move now to Claire. Claire was born on 3 10 January 1987. She was the youngest of three children 4 and the only daughter and she is described by her father 5 6 as a little girl who had overcome her early setbacks and 7 was happy, active and much loved. During her early childhood, she had suffered from convulsions, for which 8 9 she was prescribed Tegretol and then Epilim. However, 10 her convulsions appeared to have ceased from about September 1991, when she was four years old, and 11 12 she was weaned off the Epilim over a period of a few 13 months from February 1995.

On 21 October 1996, Claire's GP, Dr Savage, 14 15 referred her to the Belfast Hospital For Sick Children 16 with a recent history of malaise, vomiting and drowsiness. She was admitted to Allen Ward under the 17 18 care of Dr Heather Steen, who was a consultant paediatrician. She was seen there by a number of nurses 19 20 and doctors, including Dr Andrew Sands -- he was 21 a paediatric registrar -- who sought specialist assistance from Dr David Webb, and he was a consultant 22 23 paediatric neurologist. Precisely which of those two consultants, Dr Steen or Dr Webb, had the responsibility 24 25 for Claire's care and treatment from approximately

1400 hours onwards on 22 and 23 October 1996, together
 with the implications of that, are matters being
 investigated by the Inquiry.

4 On her admission on 21 October 1996, Claire was 5 prescribed IV fluids by the admitting doctor, Dr Bernie 6 O'Hare, paediatric registrar. Like Adam, she was 7 administered solution No. 18, which she continued to 8 receive during her time on Allen Ward. Again, the 9 appropriateness of the type, rate and volume of fluid administered to Claire are issues to be considered by 10 the Inquiry. 11

12 There are a number of other important aspects of the 13 care and treatment that Claire received during the course of her stay on Allen Ward that are under 14 15 investigation. Early in the morning of 23 October 1996 16 at approximately 2.30, before she was seen by Dr Steen, Claire suffered a respiratory arrest and was transferred 17 18 to the Paediatric Intensive Care Unit. She was seen there by Dr Taylor who was involved in Adam's kidney 19 20 transplant surgery. Dr McKaigue, who was the consultant 21 on call when Claire was admitted to PICU and Dr Crean is 22 noted as the consultant on the case note discharge 23 summary. Both of them were involved with Dr Taylor in production of the draft statement on future practice, 24 which was produced after Adam's death. 25

1 Unfortunately, Claire did not recover and she died 2 in PICU on 23 October 1996. Her death was not reported 3 to the Coroner and a brain-only autopsy was carried out 4 on 24 October 1996 with the permission of Claire's 5 parents. The basis on which such a decision was made 6 and the reasons for it are matters being investigated by 7 the Inquiry.

8 The pathologist on the autopsy report is shown to be 9 Dr Brian Herron, who was then a senior registrar in 10 neuropathology, but the report itself is unsigned. At that time, Dr Mirakhur was his consultant 11 12 neuropathologist. She is the same consultant whose 13 involvement in the production of Dr Armour's autopsy report on Adam is in issue. The autopsy report was not 14 15 conclusive. It found that the features of the brain 16 were those of:

"... cerebral oedema with neuronal migrational 17 defect and a low grade meningo-encephalitis. 18 The reaction in the meninges and cortex is suggestive of 19 20 viral actiology, although some viral studies were 21 negative during life and on post-mortem CSF. With a 22 clinical history of diarrhoea and vomiting, this is 23 a possibility, though a metabolic cause cannot be excluded. As this was a brain-only autopsy, it is not 24 25 possible to comment on other systemic pathology in the

1 general organs."

2 Claire's death certificate showed the cause of her death as cerebral oedema and status epilepticus. That 3 4 was called into question after a UTV television 5 documentary into the deaths of Adam and two of the other 6 children, Lucy and Raychel, was aired in 21 October 7 2004. Claire's parents watched that programme and it prompted them to contact the Belfast Hospital For Sick 8 9 Children about the circumstances of their daughter's 10 death. During a meeting with the Belfast Hospital For Sick Children's personnel and Claire's parents on 11 7 December 2004, a query was raised over the role that 12 13 fluid management, especially low sodium, might have 14 played in Claire's death. The reason why that was not 15 appreciated sooner by the Belfast Hospital For Sick 16 Children is a matter being investigated by the Inquiry. The coroner was notified and an inquest into 17 18 Claire's death was carried out by John Leckey on 4 May 2006. He engaged experts to assist him. 19

Dr Robert Bingham, who was paediatric consultant anaesthetist at Great Ormond Street. He pointed out that the current guidance to use fluid with higher sodium content was not in place when Claire was being treated in 1996. He referred to confusion over Claire's usual neurological status and the effects of that on

diagnosis and treatment. He presented a mixed picture: 1 2 "The hyponatraemia was probably an associated feature of Claire's condition, rather than the primary 3 4 illness. It was most likely to have been a result of the combination of raised levels of antidiuretic 5 6 hormone, together with the intravenous infusion of low 7 sodium content, although the volumes infused do not 8 account for the sodium becoming so low.

9 "I think it most likely that hyponatraemia was 10 a cause of the neurological deterioration. It is not, 11 however, possible to completely exclude the possibility 12 that the serum sodium result was an isolated artefact 13 and the deterioration was due to acute encephalopathy."

Dr Ian Maconochie, he was the consultant in paediatric A&E medicine at St Mary's London, he considered that the management plan to treat the possibility of non-convulsive status epilepticus was correct at the time of practice, as was her subsequent management in terms of her neurological presentation.

20 The verdict on inquest -- and that is a document 21 that we can pull up and see. Its reference is 22 091-002-002.

23 That found the cause of Claire's death, as you can
24 see there, to be:

25 "1(a), cerebral oedema due to (b)

meningo-encephalitis."

1

2 Then it goes:

3 "Hyponatraemia due to excess ADH production and 4 status epilepticus."

5 The coroner also made findings, principally, that 6 the degree of hyponatraemia that she suffered -- and 7 that's a fall in her serum sodium level to 121 --8 contributed to the development of the cerebral oedema 9 that caused Claire's death, but that the 10 meningo-encephalitis and status epilepticus were also causes, albeit he could not determine the proportionate 11 12 contribution of the three conditions to her death.

13 The coroner accepted Dr Steen's evidence at inquest 14 that the blood test showing 121 should have been 15 repeated and that there should have been a reduction in 16 her fluids. He noted Dr Steen's evidence that now the 17 fluid management of Claire would have been different. 18 That latter point is a matter that is to be investigated 19 by the Inquiry.

The coroner's finding gave rise to a new registration on 10 May 2006 with the cause of Claire's death so as to reflect the coroner's verdict on inquest. The reissued death certificate does not appear to have been issued until 2 February 2012. The circumstances in which there was a new registration and the issuance of

a new death certificate are all matters being
 investigated by the Inquiry.

If I turn now to Lucy. Lucy was born on 3 5 November 1998. She was the youngest of her parents' 4 three children and was described by her mother as 5 6 "a very special little girl". Lucy was admitted to the 7 Erne Hospital in Enniskillen on 12 April 2000, at about 8 19.20, about a recent history of drowsiness and 9 vomiting. She came under the care of Jarlath O'Donohoe, 10 consultant paediatrician, and was also treated by Dr Malik, a senior house officer in paediatrics, and 11 12 a number of nurses. It is understood that following 13 admission, Lucy was given a 100 mil bolus of fluids and 14 juice and that she started on IV fluids at approximately 15 22.30. The IV fluid was Solution No. 18 and it appears to have been accepted by clinicians and nursing staff 16 that this was given at the rate of 100 ml an hour. At 17 approximately 2.55 on 13 April 2000, Lucy suffered 18 a seizure and was transferred to the intensive care unit 19 20 at the Erne Hospital where steps were taken to stabilise 21 her for transfer to the Belfast Hospital For Sick Children. She was taken to the Belfast Hospital For 22 23 Sick Children in a seemingly moribund state, by ambulance, accompanied by Dr Jarlath O'Donohoe and was 24 admitted to PICU there under the care of Dr Peter Crean. 25

She was "hand-bagged" throughout the 90-minute trip by
 either Dr O'Donohoe or the nurse, Siobhan McNeill, who
 accompanied him.

For those unfamiliar with the geography, the 4 difference between those two hospitals can probably best 5 6 be appreciated by a map. If I can call up the 7 reference. There you are. If you look at that, you can 8 see, to the bottom left, the Erne Hospital in 9 Enniskillen. And then if you look across to the right, 10 you will see where the Belfast Hospital For Sick Children is. And there's a blow-up to the far right. 11 12 That map also shows you the trusts and the boards as 13 they were at that time. That's pretty much across 14 Northern Ireland she was being driven.

15 Lucy was seen at the Royal Belfast Hospital For Sick 16 Children by Dr Hanrahan, Dr Chisakuta, and by a specialist registrar in paediatrics, Dr Caroline 17 18 Stewart. Lucy was declared dead at 13.15 on 14 April and her death was reported to the coroner's office that 19 20 day. It was decided that it was unnecessary to conduct 21 a coroner's post-mortem. Quite how that decision came 22 to be made is a matter that may be investigated by the 23 Inquiry. Nevertheless, it was agreed with the consent of Lucy's parents, but apparently without the knowledge 24 of the coroner's office, that there would be a hospital 25

post-mortem. The autopsy request form, dated
14 April 2000, was sent by Dr Caroline Stewart to
3 Dr Denis O'Hara and it recorded the following clinical
4 diagnosis:

5 "Dehydration and hyponatraemia, cerebral oedema,6 acute coning plus brainstem death."

7 Dr O'Hara is the same pathologist who is referred to 8 by the coroner as having, along with Dr Bharucha, seen 9 certain slides in relation to Adam's autopsy and 10 expressed certain views. He conducted the hospital 11 post-mortem on Lucy later that day.

12 THE CHAIRMAN: If you just pause for one moment. I should 13 say now, for the record and to get this out of the way, 14 that the Doctor Denis O'Hara, who's been referred to 15 a number of times, is no relation of mine. He is now 16 dead, but he and I are not in any way related. 17 MS ANYADIKE-DANES: Thank you, sir. I should have made that 18 clear myself. Thank you for doing so.

19 Lucy's death was certified by Dr Dara O'Donoghue 20 as being caused by "cerebral oedema due to or as 21 a consequence of dehydration and gastroenteritis". 22 Lucy's death certificate showed the cause of her death 23 as:

24 "1(a) cerebral oedema, (b) dehydration and (c) 25 gastroenteritis."

On 14 April 2000, Lucy's death was notified to the 1 2 Sperrin Lakeland Trust by Dr O'Donohoe and on or about 18 April 2000, Mr Eugene Fee, who is director of acute 3 4 hospital services at the trust, took the decision to 5 instigate a review of the care that Lucy had received at 6 the Erne Hospital. The following day, on 19 April 2000, 7 Mr Hugh Mills -- he was chief executive of the Sperrin 8 Lakeland Trust -- informed Martin Bradley, who was chief 9 nurse at the Western Health and Social Services Board, 10 of the issues.

11 The review was coordinated by Mr Fee with 12 a Dr William Anderson, and he was clinical director of 13 the women and children's directorate at the 14 Erne Hospital.

15 In addition, on 20 April 2000, Mr Mills asked 16 a Mr Murray Quinn, he was consultant paediatrician at Altnagelvin Area Hospital, to contribute to the review 17 by examining the fluid regime which was adopted with 18 Lucy and providing an external paediatric opinion on the 19 20 management of her care. Dr Quinn was provided with 21 Lucy's clinical notes and asked to provide his opinion on three issues: 22

"1, the significance of the type and volume of fluid
administered. 2, the likely cause of the cerebral
oedema. 3, the likely cause of the change in the

1 electrolyte balance."

2 At that time, the Erne Hospital and Altnagelvin Area Hospital were in different trusts, respectively the 3 4 Sperrin Lakeland Trust -- in fact, we can see that on 5 the map that's still there -- and Altnagelvin Group of 6 Hospitals trust. However, as is clear from that map, 7 they were both under the same Western Health and Social 8 Services Board. The extent to which that may have been 9 significant is something that is being investigated by 10 the Inquiry.

11 Dr Quinn provided a draft report which was 12 incorporated into the final review report of Mr Fee and 13 Dr Anderson, dated 31 July 2000. The review report 14 rehearsed Dr Quinn's view that the total volume of fluid 15 intake was within the accepted range. He also stated 16 that:

17 "Neither the post-mortem result or the independent 18 medical report on Lucy Crawford provided by Dr Quinn can 19 give an absolute explanation as to why Lucy's condition 20 deteriorated rapidly, why she had an event described as 21 'a seizure' at around 2.55 on 13 April 2000, or why 22 cerebral oedema was present on examination at 23 post-mortem."

Lucy's death was not reported to the Coroner'soffice by the Erne Hospital or by the Sperrin Lakeland

1 Trust. The significance of that, as is the failure to 2 inform the coroner that a hospital post-mortem was being 3 carried out are matters that are being investigated by 4 the Inquiry.

5 The review, Dr Quinn's report and exactly what was 6 done at the Erne Hospital as a result of Lucy's death 7 was the subject of a critical UTV documentary broadcast 8 in October 2004. It is also an issue to be investigated 9 by the Inquiry as is what happened at the Belfast 10 Hospital For Sick Children after Lucy's death.

Following the inquest into Raychel's death on Following the inquest into Raychel's death on February 2003, the circumstances of Lucy's death were referred to the coroner, who applied to the Attorney General of Northern Ireland for a direction that an inquest should be held into Lucy's death.

16 On December 2003, the legal secretariat for the Attorney General's chambers notified the coroner that 17 the Attorney General had made an order, directed him to 18 carry out an inquest into the circumstances surrounding 19 Lucy's death. The coroner invited Dr O'Hara to convert 20 21 his hospital post-mortem report of 17 April 2000 into a coroner's report. Dr O'Hara furnished such a report, 22 23 dated 6 November 2003, in which he expressed the view that there were two potential causes: 24

25 "Firstly, hyponatraemia causing cerebral oedema due

to disturbance which occurs in the quantities of water moving into the brain. Secondly, bronchopneumonia, both toxic and hypoxic effects, and is also well-known as a cause of cerebral oedema."

5 He concluded that it would be difficult to be 6 certain what proportion of the cerebral oedema could be 7 ascribed to each of those processes.

8 Unfortunately, Dr O'Hara is deceased, as the 9 chairman has said, and we have only his two reports and 10 his letter to the coroner of 23 October 2003 to assist 11 us with his views on what happened, particularly in the 12 light of the opinion of Dr Edward Sumner, who was 13 engaged by the coroner as an expert. And this is what 14 Dr O'Hara said in that letter of 23 October:

15 "I have read Dr Sumner's report and believe that 16 this will pose difficulties in that he confuses matters of fact with matters of opinion and approaches the 17 18 matter in a some what 'tunnel vision' way. There is a history of a presentation which will be entirely 19 consistent with an infective condition and then there 20 21 is, as pointed out by Dr Sumner, objective evidence of 22 hyponatraemia. The problem is that both these 23 conditions can bear directly on the brain and give rise to the problems of which were the ultimate cause of 24 25 death, namely the cerebral oedema with its effect on

1

vital respiratory and cardiac centres."

The inquest was conducted by John Leckey from 17 February to 19 February 2004, and in addition to Dr Sumner's expert report, he also had the benefit of two other expert reports. There was Dr Dewi Evans, he was consultant paediatrician at the Singleton Hospital in Swansea and was engaged for Lucy's parents.

He pointed out that if Lucy had been managed 8 9 according to the basic standards of paediatric practice 10 from a district general hospital, then it was, in his opinion, extremely unlikely that she would have 11 12 developed cerebral oedema, ie treating Lucy with 13 a standard therapy for children with gastroenteritis would have prevented the cerebral oedema and prevented 14 15 the neurological collapse.

16 He also had available to him the report of Dr John Jenkins and he was senior lecturer in child health and 17 consultant paediatrician at Antrim Hospital, engaged by 18 the Directorate of Legal Services for Sperrin Lakeland 19 20 Trust. He pointed to the absence of clear 21 documentation regarding the fluid type and rate prescribed, together with clear records as to the exact 22 volumes of each fluid, which were in fact received by 23 the child throughout the time period concerned and the 24 confusion between the staff involved. 25

1 The implications of the observations of those 2 experts for lessons learned, hospital management and, 3 indeed, for governance generally are matters being 4 investigated by the Inquiry. The verdict on inquest of 5 Lucy's death -- and we can see that document, 6 031-067-113. Pull that up.

You can see the cause of death. It found:
"1(a), cerebral oedema, (b), acute dilutional
hyponatraemia, (c) excess dilute fluid, and, 2,
gastroenteritis."

11 The coroner also made findings that the dilutional 12 hyponatraemia was caused by a combination of the 13 inappropriate fluid replacement therapy, 0.18 per cent 14 saline, and a failure to properly regulate the rate of 15 infusion. There were other findings in respect of the 16 poor quality of the medical record keeping and the confusion amongst the nursing staff as to the fluid 17 18 regime prescribed having compounded the errors in fluid 19 management.

As a result of the inquest, Lucy's death certificate was amended to show the cause of her death as shown in the coroner's verdict on inquest.

I turn now to Raychel. Raychel Ferguson was born on
4 February 1992. She was her parents' only daughter and
a sister to three brothers. Her mother describes her as

a lively, chatty outgoing girl who loved fashion and 1 2 music. Raychel had never previously been admitted to hospital until she was admitted to the Altnagelvin Area 3 Hospital on 7 June 2001. Following her arrived in the 4 5 Accident & Emergency unit with a recent history of 6 abdominal pain and complaining of dysuria and nausea. 7 That's painful -- including burning -- urination and difficult urination. She was admitted to the children's 8 9 unit of Altnagelvin Hospital and came under the care of 10 Mr Robert Gilliland, who was a surgical consultant, although he did not see her during her admission to the 11 Altnagelvin Area Hospital, and apparently did not 12 13 appreciate that a patient under his care had died until 14 the day after her death.

15 Raychel was examined by Mr Makar, who was a surgical 16 senior house officer, who considered that she had acute appendicitis. The earlier complaint of dysuria was not 17 18 revisited and Mr Makar took the decision to perform an appendectomy, which was performed late that night. 19 The anaesthetists were Dr Gund and Dr Jamison, both of whom 20 21 were senior house officers. However, Dr Jamison left 22 before the completion of surgery. The records show that Raychel was commenced on Solution No. 18 at 22.15 at 23 infusion rate of 80 ml an hour. Mr Makar had initially 24 prescribed intravenous Hartmann's solution for Raychel 25

in the Accident & Emergency department, but upon being
 informed by Staff Nurse Noble that this was inconsistent
 with the common practice on the ward, Mr Makar changed
 the fluid prescription to Solution No. 18.

The fluids were continued at this rate until on or 5 6 about 2300 hours when Raychel was taken to theatre. The 7 records show that Raychel was recommenced on this fluid 8 at this rate at about 2 o'clock in the morning on 8 June 9 after the completion of surgery. As with the other 10 children, the administration of this particular fluid at the rate and in the volume that was administered to 11 12 Raychel is an issue to be considered by the Inquiry.

13 Raychel was seen by a number of nurses and doctors, including Mr Zafar -- he was a surgical senior house 14 15 officer -- Dr Joe Devlin -- he was a surgical junior 16 house officer -- and Mr Michael Curran -- he was surgical junior house officer -- who were called because 17 of Raychel's continued vomiting. Raychel was also seen 18 by Dr Jeremy Johnson, the paediatric senior house 19 officer, as a result of a seizure that she suffered in 20 21 the early hours of 9 June.

Following her subsequent collapse, Raychel was seen by a number of other clinicians, including Dr Bernie Trainor, paediatric senior house officer, Dr Brian McCord, consultant paediatrician on call, Dr Date,

specialist registrar in anaesthetics, and Dr
 Geoff Nesbitt, the clinical director and consultant
 anaesthetist.

Raychel's pupils were found to be dilated and 4 unreactive and her oxygenation deteriorated to 80 5 6 per cent oxygen and her respiratory efforts declined. 7 CT scans were performed and she transferred to the 8 intensive care unit of Altnagelvin later that morning. 9 Later on, on 9 June 2001, Raychel was transferred to 10 PICU at the Belfast Hospital For Sick Children. Again, for those unfamiliar with the geography, the distance 11 12 between the two hospitals can be seen at the map that 13 I brought up before.

14 There you see Altnagelvin at the top left. She's 15 coming down again to the Belfast, you see it there. 16 The transfer letter from Dr Bernie Trainor and 17 presented on her arrival at midday said:

18 "Very unwell, pupils dilated and unresponsive."
19 The note made of the examination of Raychel that was
20 carried out shortly after her admission to PICU and
21 prior to the brainstem tests being carried out records:
22 "Overall there appears to be no evidence of

23 brainstem function. Her limb movements are not, in my 24 opinion, of cerebral origin."

25 At PICU, Raychel came under the care of Peter

Crean -- who had not only been involved in Lucy's case, 1 2 but had knowledge of Adam's case and was noted in Claire's case -- he considered that brainstem death had 3 4 already taken place and she was also seen by 5 Dr Hanrahan, a consultant paediatric neurologist who had 6 been involved in Lucy's case. Unfortunately, Raychel 7 did not recover and, following two brainstem tests, she was pronounced dead at 12.09 on 10 June 2001, and 8 9 the coroner's office was notified.

10 At the request of the coroner, a post-mortem examination was carried out by Dr Herron, and he was the 11 12 neuropathologist who had been involved in the brain-only 13 post-mortem on Claire, and Dr Al-Husani, pathologist, on 14 11 June 2001. Dr Herron had carried out that 15 post-mortem examination on Claire when he was senior 16 registrar in neuropathology and here he is as a consultant neuropathologist. Prior to the completion of 17 18 the post-mortem report and on 12 June 2001, a critical incident Inquiry was established at the 19 20 Altnagelvin Hospital by Dr Raymond Fulton, who was the 21 medical director, in accordance with the hospital's critical incident protocol. One of the action points 22 involved a review of the continued use of Solution No. 23 18 post-operatively. 24

The post-mortem report was completed on 20 November

25

1 2001, with the clinical summary completed on

4 December 2001. The post-mortem report was provided on
21 December with input from Clodagh Loughrey, who is
a consultant chemical pathologist.

5 Raychel's death certificate shows the cause of her 6 death was "1(a) cerebral oedema and (b) hyponatraemia". 7 The inquest into Raychel's death was conducted on 8 5 February 2003 by John Leckey. He engaged Dr Edward 9 Sumner again as an expert. He reported in February 2002 10 that in his view Raychel died from:

"Acute cerebral oedema leading to coning as a result of hyponatraemia. I believe that the state of hyponatraemia was caused by a combination of inadequate electrolyte replacement in the face of severe post-operative vomiting and the water retention also seen post-operatively from inappropriate secretion of ADH."

18 The coroner also had the assistance of Dr Jenkins, 19 who had once again been engaged by the Director of Legal 20 Services and he concluded:

"My impression is that they [the doctors and nurses]
acted in accordance with the custom and practice in the
unit at that time. Raychel's untimely death highlights
the current situation whereby one sector of the medical
profession can become aware of risks associated with

particular disease processes or procedures through their own specialist communication channels, but where this is not more widely disseminated to colleagues in other specialities who may provide care for patients at risk from the relevant condition."

6 That situation that Dr Jenkins highlighted is 7 a matter that is being investigated by the 8 Inquiry.

9 The verdict on inquest -- and we can see that 10 document at 012-026-139 -- found the cause of Raychel's 11 death to be cerebral oedema with hyponatraemia as 12 a contributory factor. The coroner also made findings 13 that the hyponatraemia was caused by a combination of:

14 "Inadequate electrolyte replacement following severe 15 post-operative vomiting and water retention resulting 16 from the secretion of antidiuretic hormone."

Then we come to Conor. Conor Mitchell was born on 17 18 12 October 1987 and was subsequently diagnosed with spastic tetraplegia, a severe form of cerebral palsy, 19 20 and mild epilepsy. He was an only child, who had been 21 described by his family as "upright, full of fun, very 22 motivated and highly intelligent". On 28 April 2003, 23 Conor was taken to Dr Patterson at Moores Lane surgery in Lurgan with a sore throat and he had been vomiting. 24 Over the next few days, he continued to be unwell and 25

was vomiting, although the precise cause was unclear. 1 2 Ultimately, on 8 May 2003, Dr Doyle at the same Moores Lane surgery examined Conor and advised that he should 3 4 be taken to hospital for blood tests and 24-hours observation. Conor was taken to Craigavon Area Hospital 5 6 later on 8 May 2003, where he was admitted to the A&E 7 department with signs of dehydration and for 8 observation.

9 At that time, Conor was 15 years old. He weighed 10 approximately 22 kilos, he was of slim build and was described as having "the body habitus of an 8 to 9 11 year-old child". He was seen by Dr Suzie Budd, who was 12 13 a staff grade doctor in Accident & Emergency, and Dr Paul Kerr, who was a consultant in Accident & Emergency. 14 15 He was then admitted to the medial admissions unit --16 which is not a paediatric unit -- by staff nurse Ruth Bullas for the purposes of observation. Conor was 17 examined in the medical admissions unit by, variously, 18 Dr Catherine Quinn, who was a senior house officer, 19 20 Dr Andrew Murdock, who was a medical registrar, and Dr 21 Jill Totten, who was a junior house officer.

The reasons why Conor was not admitted into a paediatric unit or on to a paediatric ward and the implications of that for his care and treatment are matters being investigated by the Inquiry.

Whilst Conor was admitted to the medical admissions 1 2 unit, unlike the other children, he was not prescribed Solution No. 18, but instead received a combination of 3 4 Hartmann's solution and normal saline. And the extent to which the care and treatment which Conor received 5 6 both in Craigavon Area Hospital and the Belfast Hospital 7 For Sick Children was consistent with the then training 8 and teaching on fluid management and record keeping, in 9 particular the guidelines on hyponatraemia that have 10 been published by the department in 2002, are all matters that are being investigated by the Inquiry. 11

12 But over the course of the afternoon of 8 May 2003 13 and on into the evening, Conor's condition deteriorated. Staff Nurse Bullas, who having transferred from the 14 15 Philippines and was in her final month of her six-month 16 preceptorship noted that he had spasms and had developed a pink rash on his abdomen and thighs. Dr Murdock was 17 unable to find evidence of a rash, however Conor's 18 family queried whether he should be transferred to the 19 20 Royal Belfast Hospital For Sick Children and it was 21 agreed that a second opinion should be sought from the 22 paediatric team and Dr Marian Williams, the on call 23 paediatric registrar, was contacted. At about 20.30 and whilst he was being examined by Dr Williams, Conor 24 25 suffered two episodes of seizure activity in rapid

succession and stopped breathing. Several doctors then 1 2 attended Conor in a short period of time, including Dr Murdock, Dr Michael Smith, who was a consultant 3 4 paediatrician, Dr Hutchinson, who was a specialist 5 registrar in anaesthesia. And Conor required intubation 6 and ventilation, following which a CT scan was conducted 7 which showed a very abnormal scan and a sub-arachnoid bleed. Conor was then admitted to the intensive care 8 9 unit of the Craigavon Area Hospital under the care of 10 Dr William McCaughey, who was the consultant anaesthetist. He is recorded as being unresponsive on 11 12 arrival with pupils that were fixed and dilated.

13 The following day, Conor was making no spontaneous 14 effort breathing and the inpatient follow-up notes 15 record:

16 "All appearances are that this unfortunate young 17 fellow is brainstem dead."

He was transferred to PICU at the Royal Belfast Hospital For Sick Children on 9 May 2003 under the care of James McKaigue, who was a consultant paediatric anaesthetist. The reasons why and the process by which Conor was admitted to PICU at RBHSC are matters being investigated by the Inquiry, as are the implications of that admission for his care and treatment.

25 Subsequent brainstem tests were shown to be negative

and he was pronounced dead on 12 May 2003. The inquest into Conor's death was conducted on 9 June 2004 by John Leckey and he engaged Dr Edward Sumner as an expert. Despite the inquest, the precise cause of Conor's death remains unclear. The clinical diagnosis of Dr Janice Bothwell, who was a paediatric consultant at the Royal, was:

8 "Brainstem dysfunction with cerebral oedema related 9 to viral illness, over-rehydration, inappropriate fluid 10 management, with status epilepticus causing hypoxia."

Dr Herron, from the Department of Neuropathy, 11 12 Institute of Pathology, Belfast, performed the autopsy. 13 He was unsure what sparked off the seizure activity and the extent to which it contributed to the swelling of 14 15 Conor's brain, but he considered that the major 16 hypernatraemia had developed after brainstem death had occurred and that it therefore probably played no part 17 18 in the cause of the brain swelling. He concluded in his autopsy report that the ultimate cause of death was 19 cerebral oedema. Dr Edward Sumner commented in his 20 21 report of November 2003 that Conor died of the acute 22 effects of cerebral swelling, which caused coning and 23 brainstem death, but he remained uncertain why. He noted that the total volume of intravenous fluids given 24 25 was not excessive and that the type of fluid was

1

appropriate for Conor, but he queried:

2 "Was the initial rate of administration too great
3 for Conor? There was no pulmonary oedema, but his face
4 did become puffy."

5 That query was raised in his correspondence shortly 6 after the inquest verdict to Dr Jenkins dated 7 11 June 2004. And he copied that to the Chief Medical 8 Officer, Dr Henrietta Campbell and to the coroner. This 9 is what he put in the correspondence to Dr Jenkins:

10 "Having got home from Conor Mitchell's inquest, I feel I must communicate my great unease. This is the 11 12 fourth inquest I have attended in Belfast where 13 sub-optimal fluid management has been involved. There 14 was no calculation of the degree of dehydration, nor the 15 fluid deficit, and no calculation of the maintenance 16 fluids for a 22-kilogram child. My overall impression from these cases is that the basics of fluid management 17 are neither well understood nor properly carried out. 18 Has this been your experience? What is the remedy?" 19

In his response of 28 June 2004, Dr Jenkins referred to the results of a regional audit that had assessed the implementation of the hyponatraemia guidelines issued in March 2002. He went on to refer to arrangements being made by the chief medical officer for a workshop at which issues of fluid management can be discussed

between colleagues and relevant specialities within medicine and, indeed, nursing. He also referred to highlighting with the General Medical Council the issue of training in fluid administration and management and of drawing the matter to the attention to the Northern Ireland postgraduate dean and director of undergraduate medical education.

8 That audit on the implementation of the 9 hyponatraemia guidelines was the subject of a paper by 10 Dr Jarlath McAloon and Raj Kottyal. Respectively, they were consultant paediatrician and senior house officer 11 12 at the Antrim Hospital, and they published, in the 13 Ulster Medical Journal, "A study of current fluid prescribing practices and measures to prevent 14 15 hyponatraemia in Northern Ireland's paediatric 16 departments".

In summary, the paper concluded that, "the evidence 17 18 suggests that implementation has so far been incomplete", and it highlights problem areas. 19 The extent to which the March 2002 hyponatraemia guidelines 20 21 were being effectively implemented is an issue being 22 investigated by the Inquiry, as is the actions of the Chief Medical Officer and others in relation to the 23 emerging issue of the appropriate intravenous fluid 24 25 management of children in hospital.

1 If we go back to the verdict for Conor, the verdict 2 on inquest, which we can see at document 087-057-221. 3 It stated that the cause of death was to be -- we see it 4 there:

5 "1(a) brainstem failure, (b) cerebral oedema, (c)
6 hypoxia, ischaemia, seizures and infarction and, 2,
7 cerebral palsy."

The coroner also made findings. He was satisfied 8 9 that there was seizure activity in the afternoon, but 10 found that there was no evidence that any clinicians had seen the series of 10 to 12 seizures, the increasingly 11 12 vivid intermittent rash or heard the choking noises 13 described by the family. He concluded there was no evidence viral illness contributing to the underlying 14 15 causes of Conor's death and the coroner also found that 16 the fluid management at Craigavon Area Hospital was 17 acceptable.

18 So those are the children. I want now to move on to the issue of hyponatraemia and Solution No. 18. 19 20 Throughout the children's cases, there is reference to 21 hyponatraemia. What it means is relatively 22 straightforward. A working definition, simply for the 23 purposes of this general opening, Mr Chairman, is that when the blood level of sodium is lower than normal, 24 either because of an excess excretion of sodium over 25

intake and subsequent water intake/retention, or by an 1 2 excess of water intake over output diluting the serum sodium. That latter is dilutional hyponatraemia and 3 4 that is the reason most often referred to in the children's cases. To varying degrees, the extent to 5 6 which these children developed dilutional hyponatraemia, 7 how and why they did so, whether it could have been avoided, whether it could have been arrested and 8 9 reversed with appropriate treatment, and crucially, the 10 extent to which it killed them, are all matters that are the subject of the investigation into these respective 11 12 cases.

13 If I turn now to Solution No. 18. 0.18 per cent sodium chloride and 4 per cent glucose or dextrose 14 15 intravenous fluid solution, or Solution No. 18, is 16 so-called because it comprises that 4 per cent of glucose and 0.18 per cent sodium chloride with the 17 remainder being free water. This means it contains one 18 fifth of the sodium and chloride ions that are found in 19 an isotonic solution. An isotonic solution, such as 20 21 Hartmann's solution, contains approximately the same number of sodium and chloride ions as are in human 22 23 blood. Solution 18 was used intravenously with all the children, except Conor, and is at the heart of the 24 25 criticisms made of their fluid management. Low-level of

sodium content connected with the development of dilutional hyponatraemia. There is an issue, which the Inquiry's investigating, over the extent to which, at the time of Adam's admission and for some time afterwards, Solution No. 18 was a fairly standard intravenous solution for use with children. That investigation includes:

8 "1, the purpose for which it was considered that 9 Solution No. 18 could appropriately be administered at 10 the time when it was prescribed or administered to the 11 children. For example, whether it should have been used 12 as a maintenance fluid, that is to match the fluids 13 being lost or a replacement to match fluids already 14 lost.

15 "Alternatively, whether it should not have been used 16 for either purpose and, secondly, the extent to which the dangers of using too large a quantity of Solution 17 18 No. 18 or at too fast a rate should have been recognised. In other words, whether it should have been 19 20 appreciated that such use will lead to a dilution of 21 sodium in the body and a chain of events which, if 22 unchecked, would culminate in dilutional hyponatraemia, 23 leading to cerebral oedema.

24 "Thirdly the extent to which it is the presence of25 the low sodium in the Solution No. 18 in combination

with the 4 per cent glucose that presents a problem in 1 2 terms of dilutional hyponatraemia leading to fatal cerebral oedema or whether the same result would be 3 4 produced by a similar quantity and rate of 5 administration of water or glucose without sodium. 6 "The precise mechanism by which dilutional 7 hyponatraemia develops in children receiving intravenous 8 fluids together with its consequences and significance 9 are matters that will be addressed in greater detail 10 during the oral hearings for each of the children." I go now to the hyponatraemia guidance: 11 12 "Another important aspect of the work of the Inquiry 13 is the impact of the guidance 'On the prevention of hyponatraemia in children' which the department issued 14 15 in 2002 before the Inquiry was established." We can just call that up. 007-003-004. There you 16 see it. If you go to the top: 17 "Any child on IV fluids or oral rehydration is 18 potentially at risk of hyponatraemia." 19 20 And then that guidance goes on to set out in 21 bullet-point form how serious it is, what sort of failures it reflects, its complications. It then 22 23 provides simple guidance as to the baseline assessment, fluid requirements, choice of fluid, monitoring, the 24 significance of that and, most importantly, when to seek 25

1 advice.

2 It is possible that the need for such guidance was raised at a meeting on 18 June 2001 of medical 3 4 directors, within just days of Raychel's death. 5 However, the guidance itself was published on 25 March 6 2002, after the deaths of all the children, except 7 Conor. 8 The hyponatraemia guidance starts with the warning 9 that I have just read out there: "Any child on IV fluids or oral rehydration is 10 potentially at risk of hyponatraemia." 11 12 And it highlights the particular risks of the 13 condition, including those associated with post-operative patients and bronchiolitis with vomiting. 14 15 And it addresses, as I listed out before, the baseline assessment and so forth, culminating in the importance 16 of seeking advice. 17 18 The circumstances giving rise to the formulation of the hyponatraemia guidance, its implementation, 19 20 monitoring, auditing and evaluation, are a fundamental 21 part of the Inquiry's role and will be addressed in the 22 oral hearings, particularly those dealing with hospital 23 management and governance. I will move on now to the establishment of the 24 Inquiry. On 21 October 2004, UTV aired an hour-long 25

Insight special entitled "When Hospitals Kill". It 1 2 features the deaths of Adam, Lucy and Raychel, claiming they had all died of the same cause: namely by hospitals 3 4 accidentally administering too much of the wrong type of 5 intravenous fluid. It also sought to expose what it 6 claimed was a deliberate cover-up of the cause of Lucy's 7 death. The documentary prompted the department to take action, and on 1 November 2004, Angela Smith 8 9 announced -- we can pull up her announcement, actually. 008-032-093. 10

She announced that she had appointed John O'Hara, 11 12 you, Mr Chairman, to conduct a public Inquiry into the 13 issues that it raised. At that time, there was direct rule from Westminster and Angela Smith was the minister 14 15 with responsibility for health, social services and 16 public safety in Northern Ireland. The department recognised that public confidence had been damaged and 17 wished the terms of reference for the Inquiry to be 18 sufficiently broad to enable the concerns of not just 19 20 the families, but also the wider public to be fully 21 addressed. In announcing the Inquiry, the minister 22 stated:

23 "I believe it is of the highest importance that the 24 general public has the confidence in the quality and 25 standards of care provided by our health and social

services. The death of any child is tragic and it is
 essential that the investigation into these deaths is
 independent, comprehensive and rigorous."

4 That document can be called up at 021-010-022. She 5 goes on to say that:

6 "The terms of reference that I have set for the 7 Inquiry and the powers available to it are wide-ranging 8 and should ensure that the Inquiry deals with all the 9 issues of concern."

10The terms of reference were announced on1118 November 2004.021-010-024:

12 "In pursuance of the powers conferred on it by 13 article 54 and schedule 8 to the Health and Personal 14 Social Services (Northern Ireland) Order, the Department 15 of Health here appoints Mr John O'Hara to hold an 16 Inquiry into the events surrounding and following the deaths of Adam Strain, Lucy Crawford and 17 18 Raychel Ferguson, with particular reference to: 1, the 19 care and treatment of Adam Strain, Lucy Crawford and 20 Raychel Ferguson, especially in relation to the 21 management of fluid balance and the choice and administration of intravenous fluids in each case. 22

"2, the actions of the statutory authorities, other
organisations and responsible individuals concerned in
the procedures, investigations and events which followed

the deaths of Adam Strain, Lucy Crawford and Raychel
Ferguson. 3, the communications with and the
explanations given to the respective families and others
by the relevant authorities."

5 So as can be seen, the first part of the Inquiry's 6 work under the terms of reference -- and this is true 7 also of the revised terms of reference since the structure remains the same -- relates to the children's 8 9 treatment. That part of the terms of reference requires 10 an investigation into their care and treatment, plain and simple. So for Adam and Raychel, that involves an 11 12 investigation into the decisions over their surgery, 13 when it was to be carried out, who was to do it, as well as to how it was actually performed. However, that is 14 15 not everything. Attention is drawn to the management of 16 the children's fluid balances. In Adam's case, that would involve the calculations made to arrive at the 17 fluid management plan for his renal transparent surgery 18 and any adjustments made to that plan during the course 19 20 of his surgery.

Attention is also drawn to the choice of intravenous fluids. So for example, in Raychel's case, that would involve the reason for and the justification of the change from Hartmann's solution that had initially prescribed for her during her surgery to Solution No. 18

1 that was administered to her on the ward. The 2 difference between those two intravenous solutions lies 3 largely with the level of sodium, which for Hartmann's 4 is 131, whilst for Solution No. 18 is 30.

5 The second part of the terms of reference is very 6 broad and the range of persons involved is constrained 7 only by the requirement that they were concerned in the 8 procedures, investigations and events that followed the 9 children's deaths. At one level, that will involve an 10 investigation into the process by which the Belfast Hospital For Sick Children's protocol on renal 11 12 transplantation in small children was revised 13 in September 1996 following Adam's death. It extends to 14 the nature and adequacy of the Inquiry carried out at 15 the Erne Hospital into the circumstances of Lucy's 16 death, as well as the conduct of the chief medical officer at the time following Raychel's death. It also 17 18 takes in the means by which the department's guidance on 19 the prevention of hyponatraemia in children was 20 produced, the process by which it was introduced into 21 hospitals and the extent to which its enforcement was 22 audited and evaluated together with the quality of the 23 governance exercised by the department in relation to the occurrence of serious adverse incidents in 24 25 hospitals.

The Inquiry has compiled a chronology to summarise 1 2 the events and lessons learned in relation to this aspect of its work, which is being updated to reflect 3 4 the results of the investigation into the governance issues arising out of each of the children's cases. 5 6 It is intended that the first part of it will be 7 provided prior to the start of the oral hearing on the 8 governance issues in Adam's case.

9 There are, of course, other bodies whose conduct 10 in relation to the particular issues of concern may fall 11 within the scope of the Inquiry's work.

12 For example, one, the School of Medicine Dentistry 13 and Biochemical Science at Queen's University, Belfast, which provides undergraduate training and research 14 15 facilities. The school has established sub-deaneries 16 within the local health trusts to try and ensure greater integration between academic and clinical colleagues and 17 it may well prove to be an issue how successful that has 18 19 been.

Two, Northern Ireland Medical and Dental Training Agency and its predecessor, the Northern Ireland Council for Postgraduate Medicine and Dental Education. The task of both of those bodies was to ensure that doctors and dentists [although they're not relevant to this Inquiry] are effectively trained to provide patients

1

with the highest standards of care.

2 Three, the Medicines and Healthcare Products Regulatory Agency and its predecessor, The Medicines 3 4 Control Agency, which ensures that medicines and medical devices work and are acceptably safe. The commission on 5 6 human medicines is a committee of the Medical and 7 Healthcare Products Agency whose duties came into being 8 on 30 October 2005. For the purposes of this Inquiry 9 and in relation to the use of Solution No. 18, its 10 duties include advising ministers on matters relating to human medicinal products and promoting the collection 11 12 and investigation of information relating to adverse 13 reactions for human medicines for the purposes of such advice. And prior to its formation, that function was 14 15 carried out by the Medicines Commission and the 16 Committee on Safety of Medicines.

Four, there is a National Health Patient Safety Agency, which coordinates the efforts of the entire country to report and learn from mistakes and problems that affect patient safety.

21 And then fifth, there's the HPSS Regulation and 22 Quality Improvement Authority, sometimes known as the 23 RQIA, which promotes safe practice on the use of 24 medicines and products and is Northern Ireland's 25 independent health and social care regulator.

The third part of the terms of reference, though, 1 2 Mr Chairman, takes us back to the children and their families. It encompasses a range of communications, for 3 4 example the nature and extent of the information given to Adam's mother about renal transplantation at the 5 6 Royal Belfast Hospital For Sick Children, the accuracy 7 and the quality of the information given to the parents 8 of the other children as to why they became so ill and 9 died, together with the degree to which the clinicians 10 concerned listened to the concerns of the parents in all the cases. 11

12 Then if we go to the early stages of the Inquiry's 13 work, starting first with the approach. The approach to 14 the terms of reference was signalled almost immediately 15 by your statement, Mr Chairman, of 18 November 2004, 16 when you said:

17 "The terms of reference of the Inquiry, which have 18 been published today, are very broad and I believe they 19 will enable me to look at all the issues that need to be 20 examined."

The commitment to investigating the broader issues was reiterated by you, Mr Chairman, in a public hearing on 3 February 2005.

24 We can call up that little extract, it's reference 25 303-005-055. There you say:

"I am determined to get to the heart of the issues 1 2 which led to the administrative decision to establish the Inquiry, specifically that the public needs to know 3 4 that our health service is managed and organised in such a way that when unfortunate events happen, as they 5 6 inevitably will, lessons are learned to prevent their 7 repetition. Nobody can reasonably expect that mistakes will not occur in our health service. What we all 8 9 should expect, however, is that steps will be taken to 10 help to minimise the risk to the health of others in the 11 future."

12 Perhaps the single most important general issue is 13 what procedures have been in place to ensure that 14 information and lessons which emerge from inquests are 15 disseminated within the hospital concerned, within the 16 Health Service of Northern Ireland and the health service throughout the United Kingdom generally. Some 17 of the heightened concern over the incidence of 18 hyponatraemia-related deaths in Northern Ireland was 19 generated by that discovery in December 2004 of Claire's 20 21 death. That was a hitherto unknown child's death in 22 which hyponatraemia was believed to be implicated. That 23 discovery prompted an almost immediate parliamentary question from Iris Robinson, who was then the MP for 24 Strangford, on 25 January 2005 to Angela Smith, and she 25

1 asked:

2 "How many dilutional hyponatraemia-related deaths occurred in the province in each of the last 20 years?" 3 The answer was provided on 27 January 2005, and 4 5 we can pull that up at reference 073-019-093. There 6 it is. That's the table that was provided by way of 7 answer. You can see there, apart from the date, then 8 you have the deaths where the primary cause of death was 9 hyponatraemia or fluid overload. And then you have, 10 in the third column, deaths where an associated or secondary cause of death was hyponatraemia or fluid 11 12 overload.

13 You can see from that first column that there were 14 six deaths where the primary cause of death was 15 hyponatraemia or fluid overload and 55 deaths where an 16 associated or secondary cause of death was hyponatraemia or fluid overload. And as a result, Mr Chairman, you 17 18 wrote to the department seeking the number of deaths in 19 Northern Ireland in the last 25 years in which 20 hyponatraemia had been identified as a primary or 21 secondary cause of death. It also led to an 22 announcement by you, Mr Chairman, during a procedural 23 hearing on 3 February 2005, when you said:

24 "Another issue, which we want to address, is: what25 is the frequency of death as a result of hyponatraemia

in Northern Ireland? Our understanding, from figures 1 2 which we have received recently from the department, is that in the last 20 years there have been eight 3 4 deaths which have been registered as directly 5 attributable to hyponatraemia, but there have been 55 6 deaths registered with hyponatraemia as a secondary or 7 contributory factor, and 16 of those deaths were registered in 2002 and 2003. We want to enquire whether 8 9 this is in keeping with equivalent figures for the rest 10 of the United Kingdom. We want to enquire whether this is in keeping with other European countries and, whether 11 12 it is or is not equivalent to other countries, is there 13 any extent to which such deaths are avoidable?"

I will return to the Inquiry's investigation into 14 15 the incidence of hyponatraemia-related deaths in 16 Northern Ireland and how it compares with the rest of the UK and Europe. Like other issues, it has not proved 17 straightforward to investigate. But another early broad 18 issue identified by you, Mr Chairman, was the extent to 19 20 which the risk of hyponatraemia and the matters 21 addressed in the hyponatraemia guidelines issued by the department in 2002 were or could reasonably have 22 23 been expected to have been known to clinicians in Northern Ireland at the time of the treatment and deaths 24 of Adam, Lucy and Raychel in 1995, 2000, and 2001 25

1 respectively.

You made it quite clear, Mr Chairman, at the progress hearing on 23 June 2005 that you will also be looking at the education and training and at the continuing education and training of nurses and doctors. I will deal later with how the Inquiry has pursued the investigation into that issue.

8 I turn now to the progress of the work. A first 9 task for the Inquiry was to secure the relevant documents. From December 2004, requests were sent out 10 to a large number of bodies and organisations: the 11 12 Department, of course, the Royal Group of Hospitals, 13 Sperrin Lakeland Trust, Altnagelvin, the coroner, Ulster 14 Television, the families of the children Adam, Lucy and 15 Raychel. And by February 2005, the Inquiry had received 16 over 80 lever arch files from those sources.

Thereafter, the Inquiry published its initial 17 18 procedures on the Inquiry's dedicated website dealing with the procedure of the Inquiry and related matters, 19 interested parties and the context for the involvement 20 21 of experts. And in order to assist the Inquiry with its 22 work, a team of expert advisers was engaged and 23 international experts from America, Canada and Australia were appointed to peer review their work. Their 24 professional details are included in the protocol number 25

4 on experts, which is published on the Inquiry's 1 2 website. But in summary, their expertise includes paediatric anaesthesia, paediatric intensive care 3 4 nursing, health service management and patient safety. One of the first tasks for the advisers was to assist 5 6 the Inquiry with the development of a list of issues to 7 guide the investigation necessitated by the terms of 8 reference as interpreted by you, Mr Chairman.

9 The first list of issues was published on the 10 Inquiry's website in June 2005. The scale of the investigation indicated in them was evident and shaped 11 12 by the following factors. The first was the clinical 13 issues relating to the care and treatment of Adam, Lucy and Raychel and the communications with their families. 14 15 The children were all admitted with different medical 16 conditions at different times and into different hospitals and they all died in a period spanning from 17 18 November 1995 to June 2001.

A proper assessment of the care and treatment they received on their admission, as required by the first part of the terms of reference, could necessitate, in some instances, considering their previous clinical history, which in the case of Adam involves medical notes and records going back to when he was just a few months old and at the Ulster Hospital.

The second factor: the management and governance 1 2 issues relating to those clinical issues require the practices, procedures and systems in place over 3 4 a lengthy period to be considered. In the case of the education and training of the clinical staff treating 5 6 Adam, it amounts to a period from approximately 1975, 7 whereas in the case of the level of compliance with 8 guidelines on hyponatraemia, it involves a period 9 spanning 2002 to the present day.

10 In addition, and in relation to the events following the deaths of the children, it meant investigating the 11 12 practices of three separate hospitals, their respective 13 trusts and area boards as well as the Department as well. In particular, and as all three children ended up 14 15 at the Royal Belfast Hospital For Sick Children, which 16 is Northern Ireland's premier paediatric hospital and a teaching hospital, it would mean at least investigating 17 the practices in place as at Adam's admission in 18 November 1995 up to the present day. 19

Furthermore, it would require an investigation into the reporting and management structure within the hospitals, trusts and area boards together with the dissemination of information amongst clinicians in different hospitals and the institutional linkages between the different trusts, area boards, Department,

Chief Medical Officer, Coronial Service and the Medical
 School at Queen's University Belfast.

If I move on to some other matters that ran
alongside or come across the early start of the
Inquiry's work, the first of those was PSNI
investigations. Shortly after the Inquiry was
established, the Police Service of Northern Ireland
commenced an investigation into Lucy's death.

9 In January 2005, Mr Chairman, the PSNI outlined the 10 position to you as, (i) it was estimated that their investigations would be completed in time for the file 11 12 to be with the DPP by mid-April 2005. However, it was 13 explained that there were issues that might delay 14 progress such as uncovering evidence of an attempt to 15 pervert the course of justice, which would require 16 a more detailed examination of a very large number of documents held by the Sperrin and Lakeland Trust. 17

18 (ii) the PSNI was concerned that the Inquiry's investigation into the circumstances surrounding Lucy's 19 20 death might compromise their investigation and therefore 21 they wished the Inquiry to suspend its work on Lucy's 22 case pending the completion of that investigation. And 23 third, there were no plans to investigate the death of either Adam or Raychel and therefore the PSNI had no 24 objection to the Inquiry's work continuing in those 25

cases. Mr Chairman, you therefore excluded from the
 work of the Inquiry any investigation into the issues
 concerning Lucy and the Inquiry continued with its work
 into the other issues arising out of the terms of
 reference.

6 But then on 26 July 2005, PSNI wrote to the Inquiry 7 to advise that (i) they were going to start an 8 investigation into Adam's and Raychel's deaths. (ii) 9 the PPS had confirmrd that no decision would be taken 10 about any prosecutions in Lucy's case until all three files were with the DPP. (iii) they wished the 11 Inquiry (a) to remove from its website any information 12 13 which might be relevant to the police investigation, (b) 14 to provide them with all Inquiry witness statements and 15 (c) not to seek any outstanding Inquiry witness 16 statements or to generate any further such witness statements. In short, they wished the Inquiry to 17 18 suspend its work for the time being.

As a consequence, Mr Chairman, a press release was issued explaining the position and a public hearing was convened for 7 October 2005. Mr Chairman, you announced at that public hearing that the work of the Inquiry was being suspended until you received, effectively, the all-clear from the PSNI.

25 I now move on to what happened in the intervening

The intervening period was from 7 October 2005 1 period. 2 until the Inquiry resumed its work in 2008, and there were a number of significant developments during that 3 4 time. The first, of course, was the continuation of the 5 PSNI investigations. The PSNI investigations continued 6 in the three cases of Lucy, Adam and Raychel. In 7 addition, the cases of Claire and Conor also came to the attention of the PSNI and they commenced investigations 8 9 into Claire's death in July 2005.

10 On 20 October 2006, almost exactly a year after the Inquiry had suspended its work, the PPS took the 11 12 decision that the available admissible evidence was 13 insufficient to meet the test for a prosecution against Dr O'Donohoe and others for gross negligence 14 15 manslaughter of Lucy and related offences. 16 Subsequently, they took the same decision in relation to Adam's case, and on 1 February 2008 the PPS decided not 17 to proceed with any prosecutions against anyone involved 18 in Raychel's case. 19

In addition, the PSNI decided not to proceed further with any investigations into Claire's death and thereafter, in August 2008, the PSNI took the decision not to pursue any further investigations into Conor's death. Accordingly, neither of those cases was referred to the PPS.

Also, in that intervening period, were GMC and NMC 1 investigations. The Inquiry has operated alongside those investigations from the General Medical Council and the 3 4 Nursing and Midwifery Council into the conduct of certain clinicians involved in some of the children's 5 cases. Those cases proceeded whilst the Inquiry's work 6 was suspended and some of them are still ongoing. In 7 order not to fragment matters too much, I'll explain 8 9 matters here the current position in relation to those 10 cases even though some of the developments occurred after the resumption of the Inquiry's work. 11

12 The first of those investigations was instigated by 13 a report from the Coroner to the GMC on 23 February 2004 following the conclusion on 19 February 2004 of the 14 inquest into Lucy's death. The referral concerned the 15 16 conduct of Dr O'Donohoe and Dr Malik and was prompted by what the coroner described as "very serious concerns 17 18 about the quality of the medical care Lucy received 19 whilst a patient in the Erne Hospital".

20 The result of those investigations was that on 21 27 September 2008, the case against Dr Malik was 22 cancelled and on 30 October 2009, the Fitness to 23 Practise Panel of the GMC found Dr O'Donohoe guilty of 24 serious professional misconduct.

25 Then Mr and Mrs Ferguson made a formal complaint to

the GMC on 6 November 2004 about a number of clinicians 1 2 and officials. They are Dr Henrietta Campbell, who was then the Chief Medical Officer; Dr Murray Quinn; 3 Dr Hanrahan; Dr John Jenkins; Dr Geoffrey Nesbitt and 4 Dr James Kelly. The Fergusons' complaint concerned what 5 6 they regarded as a failure of all those doctors to 7 reveal the truth in the investigations into Lucy's 8 death. They believe that the death of their daughter 9 Raychel could have been avoided if Lucy Crawford's death 10 had been properly and independently investigated in 2000. 11

12 The case against Dr Jenkins and that against 13 Dr Geoffrey Nesbitt were closed on 23 January 2009 and 3 December 2009 respectively, following decisions that 14 15 no further action should be taken. The case against 16 Dr Campbell was concluded on 27 May 2010 on the basis that no further action should be taken but that she 17 should "reflect on this decision and the concerns 18 expressed by the complainants". The basis of those 19 20 concerns forms part of the Inquiry's investigations. 21 The cases against Dr Kelly are

22 continuing, so I shan't be saying any more about them.
23 On 9 November 2011, the GMC informed the Inquiry
24 that Dr Murray Quinn had applied for voluntary erasure.
25 If granted, that would bring the case against him to an

end with no findings but that he would not, of course, be able to practice in the UK. He could subsequently apply to restore his name to the medical register, but if he did so then any outstanding fitness to practise issues would need to be addressed.

6 On 15 December 2011, the GMC refused that 7 application for voluntary erasure on the basis that it 8 was not in the public interest to dispose of his case 9 in that way. As a consequence, the case against 10 Dr Quinn is also continuing.

There have been two sets of complaints to the NMC 11 12 about the conduct of nurses. The first set concerned 13 complaints made in October 2004 by Lucy's parents in relation to Bridget Swift, Sally McManus, Bridget 14 15 Jones and Teresa McCaffrey and their involvement in 16 Lucy's case. Those complaints were all investigated in 2007 and closed in January 2007 on the basis of there 17 being no case to answer. 18

19 The other complaint was made in December 2009 by 20 Conor's grandmother, Judith Mitchell, about Ruth Bullas 21 and her involvement in Conor's case. On 13 July 2011, 22 the Conduct and Competence Committee Panel of the NMC 23 found Ruth Bullas guilty of professional misconduct and 24 her fitness to practise impaired. The first of the 25 three charges concerned the failure to "document in the

nursing notes the reports that you received from patient 1 2 A's mother and grandmother that they had witnessed patient A suffering from seizures". The second 3 concerned a failure to escalate to a senior member of 4 staff for a second opinion the reports of such seizure 5 6 activity. The panel accepted the evidence of Sister 7 Irene Brennan that no one had reported any seizures, 8 spasms or twitchings to her concerning Conor and that if 9 she had been informed of that type of activity, she would have attended Conor herself. It found as part of 10 its reasons for the finding of impairment: 11

"Health care records are a tool of communication within the team. You must ensure that the health care record for the patient is an accurate account of treatment, care planning and delivery. It should provide clear evidence of the care planned, the decisions made, the care delivered and the information shared."

A striking-off order was made in respect of Ruth Bullas and the panel stated as part of its reasons for the sanctions imposed:

22 "Responsibility for the deficiencies in the care 23 provided to Conor at Craigavon Area Hospital should not 24 be born by her [that is Ruth Bullas] alone. The 25 evidence before the panel revealed further wide-ranging

and systemic deficiencies in Conor's treatment and care. 1 2 These included the fact that the registrant was delegated responsibility for Conor's nursing care with 3 4 little or no ongoing support despite her lack of 5 experience and the fact that she had not yet completed 6 her preceptorship, inadequate handovers, briefings and 7 reporting processes, a failure to provide Conor with nursing staff who were sufficiently and suitably 8 9 qualified, and a lack of timely access to paediatric facilities and expertise." 10

Whilst, Mr Chairman, you have determined that the 11 12 Inquiry is not investigating the cause of Conor's death 13 and the conduct of the nurses or other clinicians in 14 relation to his demise, you have nonetheless determined 15 that the Inquiry is investigating the issue of record 16 keeping. Accordingly, the Inquiry will investigate the significance, if any, of the findings and observations 17 18 made by the panel in Ruth Bullas' case in relation to the knowledge of the nurses at Craigavon Area Hospital 19 20 of appropriate record keeping and the hyponatraemia 21 guidelines together with the systems that the hospital instituted to introduce the guidelines, provide training 22 23 on them and then ensure that they were being followed.

I turn now to another development in the intervening period, which is Alert No. 22. On 28 March 2007, the

National Health Service National Patient Safety Agency
 issued its Alert No. 22 for one-month to 16 year-olds,
 recommending the taking of action by 30 September 2007
 to minimise the risk of hyponatraemia in children.
 We can see that at 303-026-350.

6 That action by the NPSA was a culmination of 7 a process that had been instigated as far back as 8 25 September 2001 by Dr Taylor, who reported to its 9 predecessor organisation, Medicines Control Agency, 10 through the yellow card system, a suspected adverse drug reaction in respect of intravenous Solution No. 18 and 11 12 the death of Raychel in 2001. It was welcomed by the 13 Medicines Control Agency as:

14 "An important early warning of previously 15 unrecognised adverse effects which allows us to take 16 appropriate action to improve the safe use of 17 medicines."

The progress of the investigation is summarised by 18 a Dr Katherine Cheng of the Medicines Control Agency in 19 a letter that she wrote to Dr Taylor of 26 November 20 21 2001. The Working Group on Paediatric Medicines 22 conducted a review of 4 per cent dextrose/0.18 per cent 23 saline and considered that although hyponatraemia is a risk to children during the use of 4 per cent 24 dextrose/0.18 per cent saline, electrolyte imbalance is 25

a risk with the use of all intravenous solutions.

1

2 The working group noted at its meeting on 21 November 2001 that careful monitoring of children 3 4 after surgery is crucial and, in particular, care should 5 be taken not to overload patients with intravenous 6 fluids if they were oliguric or as part of the normal 7 response to surgery. However, the working group 8 considered that the issue of hyponatraemia related more 9 to clinical practice than to medicines regulation and 10 advised that there should be no changes to product information. 11

12 Then in 2006, Way and others published in the 13 British Journal of Anaesthesia the results of a survey 14 that had been carried out to assess the practice of 15 postoperative intravenous fluid prescription by 16 paediatric anaesthetists. The results showed, amongst other things, that 75.2 per cent of anaesthetists 17 18 prescribed hypotonic dextrose saline solutions in the postoperative period. The authors suggested that 19 national guidance was required, and that led to Alert 20 21 No. 22 being issued.

Following on from the issue of Alert No. 22, on 27 April 2007 Dr Michael McBride, who was then the Chief 24 Medical Officer for Northern Ireland, Dr Norman Morrow, 25 who was the Chief Pharmaceutical Officer for Northern

Ireland, and Martin Bradley, who was Chief Nursing
 Officer, sent a joint letter to the chief executives of
 the trusts, informing them that:

4 "HSC organisations are required to implement the
5 actions identified in the alert by 30 September 2007.
6 Independent sector providers which administer
7 intravenous fluids to children will also wish to ensure
8 that the actions specified in the alert are implemented
9 in their organisations within the same time scale."

The actions identified involved the removal of 10 Solution 18 from stock and general use in areas that 11 12 treat children; the production and dissemination of 13 clinical guidelines for the fluid management of 14 paediatric patients; the provision of adequate training 15 and supervision for all staff involved in the 16 prescribing, administering and monitoring of intravenous infusions; reinforcement of safer practice by reviewing 17 18 and improving the design of existing intravenous fluid prescriptions and fluid balance charts for children; the 19 20 promotion of the reporting of hospital acquired 21 hyponatraemia incidents via local risk management 22 reporting systems; and the implementation of an audit 23 programme to ensure that NPSA recommendations are adhered to. 24

Alert No. 22, the circumstances in which it came

25

about, and the response to it will be addressed in 1 2 detail later on. However, as can immediately be seen, it went further than the hyponatraemia guidance in that 3 it recommended the removal of Solution No. 18 from stock 4 and general use in areas that treat children. And for 5 6 completeness, the Commission on Human Medicines recently 7 had a further review carried out of the use of Solution 8 No. 18 and the Inquiry awaits the publication of its 9 results and their implications, if any, for its 10 investigations. The implementation required by Alert No. 22 is to be 11 12 found in the guidance published by the Department 13 in September 2007. We can pull that up, it's at 14 303-059-817. This has now gone further than just 15 hyponatraemia guidelines, this is: 16 "Paediatric parenteral fluid therapy (1 month to 16 years): Initial Management Guidelines." 17 I will not go through it all, it's in the documents 18 for you to see. 19 The title of that guidance was amended and the 20 21 quidance was reissued in February 2007 to: 22 "Parenteral fluid therapy for children and young persons (aged over 4 weeks and under 16 years)." 23 That guidance is more comprehensive, as I've said, 24 than the hyponatraemia guidelines, and the introduction 25

of that guidance into hospitals in Northern Ireland and 1 2 the effectiveness of the systems in place for monitoring compliance with it are matters being investigated by the 3 4 Inquiry. But again, for completeness, prior to the 5 publication of Alert No. 22, the Chief Medical Officer 6 had written on 8 July 2004 to Dr Jack McCluggage, who 7 was the Postgraduate Dean of Medicine at Queen's 8 University, to request that he consider training in 9 fluid management administration a priority. 10 Dr McCluggage forwarded that request on to the senior trainers within paediatrics and other medical 11 12 specialities on 20 July 2004.

13 Dr McCluggage remained Postgraduate Dean until 14 October 2004 when he was succeeded by Dr Terry McMurray, and he wrote on 14 June 2005 to all directors of 15 16 speciality training committees, all postgraduate clinical tutors, all education coordinators and to the 17 18 director of postgraduate general practice education, requesting evidence about training being delivered and 19 20 how it had changed. And then Dr Mc Murray again wrote on 21 21 May 2008 to all the heads and deputy heads of the 22 schools of many of the key areas of practice, including foundation doctors, specifically referring to the fact 23 that: 24

25

"The development of hyponatraemia in previously well

children undergoing surgery or with mild illness may not
 be recognised by clinicians."

He enclosed the Regional Paediatric Central Fluid
Therapy Chart developed by the Department of Health as
well as a "Workforce Competence Statement" developed by
the National Patients Safety Agency to assist in
implementing and embedding the training. Dr McMurray
stressed:

9 "It is very important that training in this area is 10 addressed by your specialty and I would be grateful if 11 you can inform me as soon as possible how you mean to 12 address this issue."

On 30 June 2008, the Associate Dean for Foundation Training contacted all the foundation doctors and their educational supervisors to advise them that completion of the BMJ e-learning module on hyponatraemia was mandatory and that proof would be required of completion of the module within four weeks of starting their F1 post.

The precise communications, if any, amongst the hospitals/trusts, the Department, the coroner and university in relation to the risks associated with low sodium and poor fluid management and their significance is something that is being investigated by the Inquiry. Then just finally to the intervening period, the

RQIA. The HPSS Regulation of Quality Improvment 1 2 Authority was established by an order of 2003. It has a role in relation to the inspection, regulation, 3 4 investigation and review of performance within health 5 and social service organisations against five quality 6 themes: corporate leadership and accountability; safe 7 and effective care; accessible, flexible and responsive 8 services; promoting, detecting and improving health and 9 social well-being; effective communication and information. 10

11 The RQIA was asked to carry out an independent 12 review to provide assurance to the minister with regards 13 to the implementation of recommended actions outlined 14 within that Alert 22. In addition, the dissemination of 15 the clinical guidelines and a wall chart through the 16 trusts and independent hospitals was also reviewed.

The RQIA review team reported in April 2008. They had made a summary report following what they referred to as "validational visits" to the trusts and independent hospitals. And thereafter, it provided its full report on reducing the risk of hyponatraemia when administering intravenous fluids to children, dated September 2008.

It was acknowledged in those reports that all the health and social care trusts and independent hospitals

that had been visited had undertaken considerable work 1 2 to reduce the risks of hyponatraemia when administering intravenous fluids to children, and evidence was also 3 4 found in all the areas visited of a commitment to 5 achieve full compliance with the regulations in 6 Alert No. 22 and to disseminate the paediatric 7 parenteral fluid therapy clinical guidelines and wall 8 charts.

9 However, some concerns were expressed, and these are 10 important for us. (1) the need to ensure that measures are consistently applied in adult wards where children 11 12 are treated. (2) the continued presence of Solution No. 13 18 in stock on site. (3) that the provision of fluid management training for non-paediatric staff caring for 14 15 older children on adult wards was poor across all 16 organisations visited by the review team. (4) that there was little evidence of a reporting culture for 17 18 incidents relating to intravenous fluids and hyponatraemia. 19

The RQIA published a follow-up report in May 2010: "Report of actions taken by HSC trusts and independent hospitals to implement recommendations ..." They found that Solution No. 18 had been completely removed from all clinical areas where children were treated. In addition, they found that members of staff

were aware of the clinical guidelines and that nursing 1 2 staff had attended training in paediatric fluid administration. There was some concern that generic 3 4 adult fluid balance charts were still being used for 5 some paediatric patients rather than dedicated 6 paediatric equivalents and over the continuing risk 7 associated with the administration of intravenous fluids to children on adult wards and clinical areas. 8

9 That latter issue, which was referred to at page 15 10 of the May 2010 report, was a matter of concern in Conor's case when, in May 2003, he was treated in an 11 12 adult unit at Craigavon Area Hospital. And the extent 13 to which Alert No. 22 has been implemented by trusts and 14 hospitals in Northern Ireland and how they have 15 responded to the reports of the RQIA are issues that are 16 being considered by the Inquiry.

17 THE CHAIRMAN: Just pause for a moment. The issue about 18 children on adult wards, does that come about because 19 there is no uniformity of approach about what age 20 children --

21 MS ANYADIKE-DANES: I think that's --

22 THE CHAIRMAN: At what age you stop being a child for the 23 purposes of --

24 MS ANYADIKE-DANES: That's correct.

25 THE CHAIRMAN: -- of going to a children's ward or an adult

1 ward.

2 MS ANYADIKE-DANES: That's correct.

THE CHAIRMAN: So if the training and the steps which have 3 4 been taken to improve matters seem to be reasonably 5 impressive on the children's wards, that's fine for the 6 children there, but it does not necessarily help the 7 slightly older children who are on adult wards if the staff there have not received the training. 8 MS ANYADIKE-DANES: That's correct. It also is relevant to 9 10 ascertain exactly how they define a child, whether 11 they're defining a child by the child's chronological 12 age or defining a child by its physique. Conor was 15, 13 but he had, as it was described, the body habitus of 14 an 8 to 9 year-old.

15 THE CHAIRMAN: Thank you.

MS ANYADIKE-DANES: If I turn now to the work when the Inquiry resumed in 2008. It formally resumed with a progress hearing on 30 May 2008, and you announced then, Mr Chairman, that there were to be no criminal prosecutions in any of the cases and therefore the way was clear for the Inquiry to resume its work.

22 Mr Chairman, you explained that the intervening 23 years had brought about changes in that the Inquiry team 24 had changed. Mr and Mrs Crawford did not wish the 25 Inquiry team to investigate Lucy's death and the work

of the Inquiry was to be expanded to include Claire's
 case and aspects of Conor's case.

So I turn now to that, the addition of Claire and 3 Conor. In the exercise of your discretion, Mr Chairman, 4 you added the case of Claire and aspects of Conor's 5 6 case. Both deaths had come to your attention after the 7 start of the Inquiry. The inquest into Claire's death 8 took place on 4 May 2004 and hyponatraemia was found to 9 be a contributory factor in her death. The basis upon which Claire's death was included in the work of the 10 Inquiry was explained by you, Mr Chairman, during 11 12 a public hearing on 30 May 2008. Although we can call 13 it up, it's probably just as quick for me to recite what 14 vou said:

15 "In broad terms, however, my concern is about the 16 apparent conflict between the initial explanation given to the Roberts family and the subsequent explanation 17 18 given to them after, but only after, they contacted the Royal following the television broadcast. I am also 19 concerned whether more should have been learned from 20 21 Adam's death and inquest and whether there should 22 therefore have been better fluid management in the Royal 23 for Claire a relatively short time later."

24 Despite the fact that Claire's death is not included 25 in the terms of reference, her case is being

investigated, Mr Chairman, according to precisely the 1 2 same terms as those for Adam and Raychel. Therefore the Inquiry is concerned to investigate (i) Claire's care 3 4 and treatment from her admission to the Royal Belfast 5 Hospital For Sick Children on 21 October 1996 until her death in PICU on 23 October 1996. And as with the cases 6 7 of Adam and Raychel, special attention is being paid to 8 the management of Claire's fluid balance, for example 9 how often her serum sodium level was checked, whether she should have received the particular type of fluid 10 she did at the rate that it was administered. However, 11 12 her treatment also includes other elements including, l 13 for example, the monitoring of her neurological symptoms and her admission to PICU. 14

15 It also involves investigations into the way in 16 which the aftermath of Adam's death and his inquest were handled and any impact on Claire's care and treatment at 17 the Royal that they might have had. It will be 18 appreciated that Adam died at the Royal in November 1995 19 20 and the verdict in his inquest was given in June 1996 21 which was, in the case of his death, almost one year before Claire was admitted but, in the case of his 22 23 inquest, almost exactly four months before she was admitted there. 24

The second part of the terms of reference requires

25

an investigation into the actions of the statutory 1 2 authorities, other organisations and responsible individuals concerned in the procedures, investigations 3 4 and events that followed her death. At an immediate 5 level, it involves an investigation into what happened 6 immediately after her death, including therefore the 7 brain-only post-mortem that was carried out by the 8 hospital. However, it also extends to an investigation 9 into why it was that there was no inquest into Claire's death until 2006, following the action of her parents to 10 raise the matter with the Royal in 2004 after the chance 11 12 viewing of the UTV documentary.

13 Then the third part of the terms of reference concerns the communications with and explanations given 14 15 to Claire's family and others by the relevant 16 authorities. This area of investigation therefore includes an investigation into the information provided 17 to Claire's family about her condition, the conduct of 18 a brain-only post-mortem as well as the information 19 20 given to them during the meeting at the Royal in 21 December 2004, following the airing of that documentary.

The inquest into Conor's death took place on June 2004. It did not conclude that hyponatraemia played a role in his death. Nevertheless, there were criticisms of fluid management and the record keeping,

and concerns were also raised about the extent to which
 hyponatraemia guidelines had been followed and the
 significance of Conor being admitted to an adult ward.

Ultimately, on 4 February 2010, Mr Chairman, you
decided to include certain elements of Conor's case into
the Inquiry's work on the following basis:

7 "It is obviously a matter of concern if guidelines 8 which have been introduced as a result of a previous 9 death or deaths and which are aimed at avoiding similar 10 events in the future are not properly communicated to hospital staff and followed. It is relevant to the 11 12 investigation to be conducted by the Inquiry whether and 13 to what extent the guidelines have been disseminated and followed in the period since they were published. 14 15 Another matter of [concern] is whether the fact that 16 Conor was being treated on an adult ward rather than the children's ward made any difference to the way in which 17 it appears that the guidelines may not have been 18 followed. Accordingly, the Inquiry will investigate the 19 20 way in which the guidelines have been circulated by the 21 Department, the way in which they have been made known 22 to the hospital staff and the steps, if any, which were 23 taken to ensure that they were being followed. While this is an issue of general importance, it will be 24 25 informed by an examination of the way in which

guidelines have been introduced and followed in
 Craigavon Area Hospital by May 2003."

Conor's case is therefore being investigated in 3 relation to issues concerned with the hyponatraemia 4 guidelines, for example issues such as the rate, choice 5 6 and volume of fluid administration appropriate to his 7 case, whether his fluid management was adequately monitored and recorded and documented and whether, if 8 9 his fluid management was inadequate, what was done about 10 it, both at the Craigavon Area Hospital and in the Royal from the perspective of governance and lessons learned. 11

12 Shortly after the Inquiry resumed and as a result of 13 the request from Mr and Mrs Crawford to have Lucy's case removed from the work of the Inquiry for their own 14 15 personal reasons, the terms of reference were revised, 16 and it came about in this way. The then Minister of Health, Michael McGimpsey, acceded to the Crawfords' 17 request, which required the removal of Lucy's name from 18 the terms of reference. In fact, we can pull up the 19 20 terms of reference, the revised ones, at 303-034-461. 21 THE CHAIRMAN: The amendment in effect is to remove Lucy's 22 name. MS ANYADIKE-DANES: Exactly. As you see there, the named 23

children are simply Adam Strain and Raychel Ferguson.
In all other respects, the terms of reference remain the

1 same.

2 THE CHAIRMAN: Claire and Conor come in under (a) at the bottom of the page, which gives me the discretion to 3 examine and report on any other matters. 4 5 MS ANYADIKE-DANES: That's correct. In fact, there was 6 a specific query, Mr Chairman, as to whether you 7 required the terms of reference to be revised to include 8 them, and you, Mr Chairman, took the view that you had 9 that power and there was no need for those terms of 10 reference to be revised simply to include Claire and Conor, and that's exactly how the matter proceeded. 11 12 But that left what interpretation should be given

13 the revised terms of reference. The minister left that matter entirely to you, Mr Chairman, and he was mindful 14 15 of the independence of the Inquiry and he was also 16 mindful of the fact that the Inquiry is investigating to a certain extent the officials, past and present, of his 17 department. So he left that matter to you and, in 18 response to that, Mr Chairman, you published 19 20 a consultation paper, canvassing ways in which the 21 revised terms could be interpreted. It is correct to 22 say that a particular aspect of it is what, if any, 23 would be the significance in terms of the successive deaths of the fact that Lucy's name was being removed. 24 Ultimately, Mr Chairman, you published your decision on 25

1 that and that is -- I think we can call it up at 2 reference 303-036-464. There you are. Those were the 3 options that you gave. If we go to 7(b), that actually 4 was your decision:

5 "The terms still permit and indeed require an 6 investigation into the events which followed Lucy's 7 death such as the failure to identify the correct cause of death and the alleged Sperrin Lakeland cover-up 8 9 because they contributed, arguably, to the death of 10 Raychel in Altnagelvin. This reflects the contention that had the circumstances of Lucy's death been 11 12 identified correctly and had lessons been learned from 13 the way in which fluids were administered to her, 14 defective fluid management would not have occurred so 15 soon afterwards (only 14 months later) in Altnagelvin, a 16 hospital within the same Western Health and Social Services Board area." 17

So that was your decision, and that was the basis
upon which we were going to move forward and conduct the
work under the revised terms of reference.

21 So issues such as steps taken by the Royal Belfast 22 Hospital for Sick Children to ascertain the cause of 23 Lucy's death, why a coroner's post-mortem was not 24 carried out and the adequacy of the Erne Hospital's 25 investigation into her death were all matters to be

investigated by the Inquiry because of the possible
 impact that they might have on the care and treatment
 provided to Raychel at the Altnagelvin Area Hospital,
 just over a year later, and her subsequent death at the
 Royal.

6 THE CHAIRMAN: And just to pause there, the point here 7 is that Mr and Mrs Crawford do not want an Inquiry into 8 Lucy's death. The minister has accepted that request, 9 but we are trying to strike a balance because Mr and 10 Mrs Ferguson believe that had there been a proper 11 investigation into Lucy's death, Raychel's death a short 12 time later may have been avoided.

13 MS ANYADIKE-DANES: That is correct.

14 THE CHAIRMAN: So we are trying to respect as much as we can 15 the Crawfords' wishes and their privacy while at the 16 same time giving the best investigation that we can into 17 what preceded Raychel's admission into Altnagelvin and 18 her death.

MS ANYADIKE-DANES: Yes, that is the line we're trying to strike. If we bring all those developments together, the revised terms of reference and the exercise of your discretion, Mr Chairman, in 2008 and 2010, that has required the following matters to be investigated: the care and treatment of Adam, Claire and Raychel, especially in relation to the management of fluid

balance and the choice and administration of intravenous 1 2 fluids; the circumstances of the death of Conor Mitchell in the context of the guidelines on fluid management in 3 4 children; the actions of the statutory authorities, 5 other organisations and responsible individuals 6 concerned with procedures, investigations and events 7 which followed the deaths of Adam, Claire, Lucy --8 in the respect in which you have just said, Mr Chairman, 9 in relation to the failure to identify the correct cause 10 of death and the alleged Sperrin Lakeland cover-up, the death of Raychel, and then Conor and 11 12 in relation again in the way that you have defined it, 13 in relation to the guidelines on fluid management in children, and then also the communications with and 14 15 explanations given to the families and the 16 recommendations to the Northern Ireland Department of Health and Social Services and Public Safety. All of 17 18 these are the matters that are now being investigated and have been for some time by the Inquiry. 19

Those issues are reflected in the Inquiry's list of issues. The list of issues is a working document, Mr Chairman, and that is updated and revised as appropriate. The current list of issues was published by the Inquiry on 14 February 2012. If we take first the clinical matters which are associated with the care

and treatment provided to the children, your 1 2 interpretation, Mr Chairman, of the revised terms of reference has translated into the following way. And 3 4 I just give some examples of that so that people can understand how we've been pursuing this. If one takes 5 6 the first as an example, the underlying principles, the 7 calculations and the assumptions made in relation to the 8 prescription of intravenous fluids before, during and 9 after Adam's renal transplant surgery. We can look at that at 303-038-479. Maybe these can just come up. 10

11 1.2(3). That's how that issue was derived. Then 12 if we move on, there's the adequacy and frequency of the 13 tests undertaken during Claire's admission and the tests 14 which could have been carried out on her between 21 --15 and just to give the reference as I'm speaking, it is 16 303-038-486.

The tests that could have been carried out on her between 21 and 23 October 1996, include the blood and urine tests, a CT scan, an electro-encephalogram, EEG commonly known as, and MRI scan. These are just examples of what the investigation means if you go to those lists of issues and translate them into actual lines of investigation.

24Then, Mr Chairman, because you've mentioned Lucy, if25you look at how the cause of Lucy's death was

established and agreed, including how and when the clinicians responsible for Lucy's treatment discussed and agreed on a cause of her death, that being the starting point of what was done thereafter or what could have been done thereafter. One sees that at 303-038-492.

7 Moving on to Raychel to see how some of this translates into a line of investigation for her. 8 9 That is 303-038-494. That is whether there was a delay 10 on the part of the surgical team responding to calls from the nursing team to see Raychel and, if so, why 11 12 that delay occurred, whether nursing staff should have 13 taken any further steps to secure the prompt attention 14 of a member of the surgical team. Did any of that 15 impact adversely on Raychel's care? Those are lines of 16 enquiry in her case. Then if one goes to 159, 303-038-494, whether the nursing and medical teams who 17 18 cared for Raychel adequately monitored her condition, whether they provided her with appropriate treatment 19 before and after she suffered a tonic seizure. 20

Then if we go down to Conor at 303-038-497, to what extent the care and treatment which Conor received both in Craigavon Area Hospital and the Royal was consistent with the then teaching and training on fluid management and record keeping, and in particular the guidelines.

That's the clinical side of it, but obviously, 1 2 Mr Chairman, there is also the management and governance side of matters. That's meant a consideration of issues 3 4 at all levels, really, from the Department, including the Chief Medical Officer, to the relevant trusts and 5 6 boards down to the management of the individual 7 hospitals and right down to the specific hospital divisions and clinical directorates. Those 8 9 considerations deal potentially with a very broad 10 spectrum, including the formulation of policy and guidance, the development of health strategy and the 11 12 establishment of governance structures, systems and 13 procedures so as to enable the standard of health care 14 being delivered to be properly monitored, audited, 15 evaluated and, of course, improved.

Examples of the extent of that range, if you go to 303-038-484, that's the procedures and practices that existed in Northern Ireland at the time of the children's deaths for the reporting and dissemination of information to the department and the medical community in general of unexpected deaths in hospitals and outcomes of coroners' inquests.

Then if we move on to 303-038-483, we come on to training and teaching, which is something that you had earlier identified, Mr Chairman. The teaching and

training to medical students and student nurses in Northern Ireland on fluid management with particular regard to hyponatraemia and record keeping and drug prescribing and administration as part of their qualification and to doctors and nurses as part of their induction, training and continuous professional development.

And then if we go on to guidelines, I give an 8 9 example at 303-038-482. What I'm going to say now 10 applies across the board, really, but this is one example taken from Adam. The guidelines, procedures and 11 12 practices that existed within the Altnagelvin Area 13 Hospital, Craigavon Area Hospital and the Royal Belfast 14 Hospital For Sick Children governing the provision of 15 information to the parents of paediatric patients.

And then just two final ones to see the span of it. 303-038-502. That is a system of protocols, procedures and practices by which hospitals in Northern Ireland code the causes of deaths and adverse incidents. Then finally, 303-038-490, the accuracy and quality of information provided by the treating physicians to the pathologists for post-mortem.

23 Mr Chairman, that's the span of the issues. Then,
24 of course, one deals with the institutions and the
25 personnel involved. In order to appreciate the scope of

the investigation that has been and is being carried 1 2 out, one really needs to say something about those two things. At the time of Adam's admission to the Royal 3 Belfast Hospital For Sick Children on 26 November 1995, 4 5 Northern Ireland was under a code of direct rule from 6 Westminster with the Secretary of State for 7 Northern Ireland responsible for the departments of the 8 Northern Ireland government. The Secretary of State for 9 Northern Ireland at that time was Sir Patrick Mayhew. He was also in office at the time when Claire was 10 admitted to the Royal Belfast Hospital For Sick Children 11 12 on 21 October 1996. He was succeeded in 1997 by 13 Mo Mowlam, who was in turn succeeded in 1999 by Peter 14 Mandelson.

15 Under direct rule, the Northern Ireland Department 16 of Health was under the remit of the Parliamentary Undersecretary of State of the Northern Ireland office. 17 The minister responsible for health care in Northern 18 Ireland at the time of Adam's admission was Malcolm 19 Moss. The structure of the Health Service in 20 21 Northern Ireland at the time of Adam and Claire's 22 admission to the Royal and their deaths there in 1995 and 1996 is shown in -- and I've just compiled 23 something, which hopefully will set that out. I've 24 called it up now at 303-039-505. 25

This is pre-2007. As some of you may have 1 2 appreciated, there was a reorganisation of the service in 2007, but this is how it was when the children who 3 4 are at issue here were being admitted and treated. You can see at the top, there's the Secretary of State for 5 6 Northern Ireland, cascading down to the minister, the 7 Department of Health, and then you see across the boards and so forth, and into the trusts. 8

9 Mr Chairman, you'll appreciate that things changed 10 fundamentally, of course, with the Belfast Agreement on 10 April 1998, and it entered into force on 2 December 11 12 1999 and ushered in a period of devolution. The 13 significance of that so far as this Inquiry is concerned is that it resulted in the Department's order of 1999, 14 15 which established the Department of Health and Social 16 Services and Public Safety as a devolved department. The first minister of the department was Bairbre de 17 18 Brun.

Devolution has been suspended on four occasions, starting with 12 February 2000. So the ministers responsible for health and social care in Northern Ireland from 1994 until the present day, including through the periods of direct rule, are shown in a chart which we've compiled, and I can call that up at 303-041-507.

1 There you are, sir. Then you see there's Malcolm 2 Moss. Under his tenure, if I can out it that way, the 3 following occurred: Adam's death on 28 November 1995, 4 Adam's inquest, Claire's death. Then you have, 5 May 1997, Tony Worthington, still under direct rule. 6 July 1998, John McFall, still under direct rule.

7 Then 2 December 1999, Bairbre de Brun, and while she 8 was there, there was Lucy's death on 14 April 2000. 9 12 February 2000, George Howarth, and the following 10 occurred during his tenure. That was when Lucy's death 11 occurred on 14 April 2000.

12 Then you have Bairbre de Brun coming in on 13 30 May 2000, and you have Raychel's death in June 2001, 14 the production and publication of hyponatraemia 15 guidelines, and then you have another period of direct 16 rule, 14 October 2002, with Des Brown.

Over the page, to 508, is 2003. You have Angela 17 Smith. Quite a bit happens there. Raychel's inquest, 18 Conor's death, Lucy's inquest, Conor's inquest, and 19 of course, the Inquiry is established. Sean Woodward 20 21 comes in in 2005, the Inquiry is suspended for a period there for reasons we've already heard about the PSNI. 22 23 2006, Paul Goggins, and during that period there's Claire's inquest, Alert 22, and the requirement to 24 implement it by September 2007. All of that happened 25

1

during the period of direct rule.

2 Then we get back to devolved government on 8 May 3 20007, Michael McGimpsey, and the Inquiry resumed during 4 his tenure and is continuing under the tenure of Edwin 5 Poots.

6 The significance of those periods of direct rule, if 7 any, is a matter that the Inquiry will consider in terms 8 of its impact on any of the issues arising out of the 9 terms of reference or the revised terms of reference. 10 In June 2002, the Northern Ireland Assembly Executive launched the review of public administration with a view 11 12 to putting into place modern accountable and effective 13 arrangements for public service delivery and the final outcome was announced by the Secretary of State 14 15 in November 2005, and it led to a major reorganisation 16 of health and social care, which was to take place in two phases. The first phase was the establishment of 17 five new integrated health and social care trusts, 18 effective from 1 April 2007. And they replaced the 19 20 trusts which had been in operation during the cases of 21 all the children. The original Health and Social 22 Services boards remained in place until the introduction 23 of the second phase in April 2009, and that involved their replacement by the Health & Social Care Board. 24 In addition, seven local commissioning groups were 25

created in April 2007. They were ultimately reduced to 1 2 five with the boundaries aligned to those of the trusts in 2009, and prior to that reorganisation, the four 3 boards had commissioned services from the trusts, and 4 the functions of the local commissioning groups was to 5 6 assess and plan for current and emerging health and 7 social care needs and to deliver the health and social care to meet those needs. We can look at that structure 8 at 303-042-509. 9

10 There we see it. This is really showing you pre-April and then post 2009, so you can see the 11 12 position in relation to the boards. If one looks at the 13 boards, you've got the four there and after April 2009 you have one. Then if we look at the health and social 14 15 services trusts pre that, you see the number of trusts 16 there and post-April 2007, you see that there's four. Then if one looks at the acute hospitals --17 THE CHAIRMAN: Five. Sorry, I think there are five. 18 MS ANYADIKE-DANES: There are five, sorry. I beg your 19 20 pardon. Failure of arithmetic. There's five.

Then if you go down to the local commissioning groups and see the position previously, and then you see it post-April 2009.

I think we can have a look at a map that also helps. If we look at 300-002-002. Now you can see the position

1

when the commissioning bodies are not aligned.

If we call up 300-078-149. You can see there also where the trusts are, the commissioning group boundaries, and you see where the hospitals are.

5 In broad terms, the function of those organisations, 6 therefore their relevance to the work of this Inquiry, 7 because that's what's at issue here -- the Department of 8 Health has overall authority for health and social care 9 services in Northern Ireland and to allocate government 10 funding for that purpose. That authority includes a formulation of policy and legislation for hospitals. 11 12 The Health & Social Care Board and its predecessor 13 regional boards are commissioners of health and social 14 services in large part. Five trusts, of which three are 15 particularly involved in the work of the Inquiry, are 16 responsible for the provision of the health and social care services. Each trust manages its own staff and 17 18 services and controls its own budget. The Royal Group of Hospitals Trust is, of course, particularly concerned 19 20 with the work of the Inquiry as it concerns the Royal 21 Belfast Hospital For Sick Children where all the children received their final care and treatment and, 22 23 ultimately, died. And the structure of that trust, as it was in 1995 and 1996, when Adam and Claire were 24 admitted, is shown in -- we can pull it up --25

1 303-043-510.

2	You see at the top, a chairman. Then down to its
3	chief executive. Then you see the non-executive
4	directors and the executive directors. If we just move
5	to the medical side for the moment, you can see the
6	medical director off to the far right; Ian Carson. Then
7	you can see the directorates there, and for our
8	purposes, names we have already heard: Joseph Gaston,
9	anaesthetics theatre and intensive care. And you can
10	see others who look as if they might be relevant:
11	Medical, Professor Gary Love; radiology to some extent,
12	Dr James Laird; surgical, Mr John Hood; and paediatrics,
13	Dr Mulholland.
14	Then you can see a name that you have already heard
15	of. If we look at the medical administration and see
16	Dr George Murnaghan and see where he fits into the
17	picture. Just above "pharmacy".
18	THE CHAIRMAN: It's in the middle of the diagram.
19	MS ANYADIKE-DANES: That's exactly right. So there you see
20	how he fits into that. His name has been mentioned many
21	times and there he was as a director for medical
22	administration.
23	If we come out again, you can see nursing and
24	patient services is there with Miss Elizabeth Duffin.
25	She was also at that level of level, director of nursing

1 and patient services also.

2 So that's how it looked in 1995/96. The Royal Group of Hospitals, therefore the Royal Belfast Hospital For 3 4 Sick Children and now within the Belfast Trust, the 5 structure of which is shown in a chart which we've 6 compiled to try and show the present day position. 7 That is at 303-044-511. Personalities have changed and 8 the structure is slightly different as well. If we go 9 to the far right side again, you can see now -- yes, 10 they have a medical director, but alongside of that, director of cancer and specialist services, and that's 11 where nephrology is located. 12 13 THE CHAIRMAN: Thank you. 14 MS ANYADIKE-DANES: The hospitals within those trusts are 15 where the health and social care services are actually 16 delivered, of course, and the work of this Inquiry is particularly concerned with five of those hospitals. 17 The Royal Belfast Hospital For Sick Children --18 THE CHAIRMAN: Shall we just call it The Children's 19 20 Hospital? 21 MS ANYADIKE-DANES: We can. The Belfast City Hospital, 22 Erne Hospital, Altnagelvin and Craigavon. So those are 23 the institutions and then if we go to the personnel, there are a large number of persons at the level of 24 25 clinicians, technicians and administrators involved

in the investigation of both the clinical issues and the 1 2 management and governance issues. Of particular relevance to the work of the Inquiry are those who were 3 4 directly involved in the care of the children during 5 their final admission to their local hospital, and where 6 relevant, following their transfer to The Children's 7 Hospital, those who had the responsibility for communicating with the children's families in respect of 8 9 consent, aspects of the children's case and/or the 10 reasons for their death, those who were involved in the post-mortem investigations into the cause of the 11 12 children's death and for the provision of the reports on 13 autopsy or post-mortem reports on the children, those who have the authority to require investigations into 14 15 and reviews of the care and treatment of the children 16 and of their deaths, and those who were actually involved in any such investigations and those who were 17 18 in the coroner's office involved in any decision in respect of the holding of an inquest into any of the 19 children's death and the coroner for the inquest into 20 21 each of the children's death and those who were and are 22 responsible for the development, implementation, audit 23 and evaluation and revision of health policy, guidance and practice in the respects in which this Inquiry is 24 25 concerned.

A number of the clinicians and pathologists were 1 2 involved in more than one of the children's cases, and that may be relevant for the investigation on lessons 3 4 learned and governance. And it raises its own issues, 5 which are matters that are being investigated by the 6 Inquiry as to who had relevant knowledge and experience 7 and the impact that that should have had on the care 8 provided to the children and also what happened in the 9 aftermath of their deaths. Those involved in that way 10 in the key disciplines of anaesthesia, neurology and pathology are set out in a chart which we have compiled 11 to try and assist and that can be called up at 12 13 303-045-512.

Across the top are the children, and then you see the anaesthetist. Dr Robert Taylor, consultant paediatric anaesthetist as he was throughout the period. If we expand a little bit. There, he was the consultant for the renal transplant operation for Adam. He examined Claire and he also examined Conor on a ward round.

Staying with the anaesthetists, look at Peter Crean.
He was a consultant during the previous operations. He
assisted in drawing up the draft recommendations.
That's Adam. As for Claire, he's noted as consultant
for her case note discharge summary. He treated Lucy

when she was transferred to the children's hospital he had overall responsibility for Raychel's care when she was transferred and he also made the diagnosis of brainstem death in her case.

5 If we just move up a little bit, we see Seamus 6 McKaigue. He is another consultant paediatric 7 anaesthetist. He assisted in drawing up the draft 8 recommendations for Adam. He was consultant on call 9 when Claire was admitted and he also examined Conor.

10 If you look at Anthony Chisakuta, he was senior registrar in anaesthesia and was consultant from 1997. 11 12 He had previously anaesthetised Adam, not in relation to 13 his transplant surgery, but previously and some of that may become relevant as we look into more detail in 14 15 Adam's case. And if we go across to Lucy, he made the 16 diagnosis of brainstem death. And if we go right across, he accepted Conor for transfer to PICU in the 17 children's hospital. 18

19If we now look at the neurologists, there is20David Webb. He carried out the brainstem tests on Adam21and he examined Claire on a number of occasions as the22consultant paediatric neurologist. If you look at23Dr Hanrahan, he treated Lucy and he made the diagnosis24of brainstem death in Raychel.

25 Over the page to 513. We can look at the surgeons.

He had previously assisted on some surgery on Adam, not
 his transplant surgery, and he also had the care of
 Raychel.

Go down to pathologists. Let's finally look at the pathologists. Brian Herron, who is involved in three: in Claire, Raychel, Conor. Dr Mirakhur, there's an issue we're pursuing in relation to Adam. And also in relation to Claire. And Dr Denis O'Hara, he was involved in two: Adam and Lucy.

10 There is also a similar overlap in relation to the management of the Royal hospitals, of which the 11 12 children's hospital, of course, forms a part. I single 13 out The Royal because it is the hospital which alone saw and treated all the children immediately prior to their 14 15 deaths, and Mr William McKee was chief executive when 16 each of the children was admitted to the children's 17 hospital.

The position in relation to the medical director, 18 the nursing and patient services director, which were 19 20 both executive director positions, is a matter being 21 investigated by the Inquiry. So too is the position 22 in relation to the directors of the key directorates of 23 anaesthesia, theatre and intensive care, paediatrics, surgery, neurosciences, laboratories, radiology and 24 medical administration. And that raises questions about 25

the unique opportunities that the Royal hospitals and the children's hospital, in particular, had for lessons learned and the dissemination of any learning which are matters that the Inquiry is investigating.

In addition to those who were directly involved 5 6 in the sense that I have just outlined, there are 7 a number of others whose conduct and/or views are 8 relevant to the work of the Inquiry. An example of 9 those are those who acted as experts, whether during an 10 inquest or during the investigations by the PSNI, and the evidence of all those involved will be provided in 11 12 a variety of ways: statements they provided to others, 13 whether to their employer, as some did, to the Royal; 14 depositions that have been given to the coroner; 15 statements given to the PSNI, together with any document 16 that they supplied, as some did, in support of their position; depositions of experts given to the coroner 17 18 together with their reports, whether they were engaged by the coroner, the families or PSNI; witness statements 19 20 given to the Inquiry, of which there is now 21 a considerable number and once again any documentation 22 that has been supplied in support of their views. And 23 of course, there's the reports of experts that the Inquiry has engaged and then the testimony of those who 24 will give their evidence at these oral hearings. 25

How has the work of the Inquiry been carried out?
The legal team comprises me as senior counsel to the
Inquiry, Jill Comerton, Martin Wolfe, both junior
counsel to the Inquiry, together with David John Reid,
who is junior counsel, and he has provided what can only
be described as invaluable assistance.

In addition, Anne Dillon, who is solicitor to the
Inquiry, and Brian Cullen, who is the assistant
solicitor to the Inquiry. I have also had the
assistance, I should say, of other solicitors, in
particular Fiona Chamberlain, who was a solicitor to the
Inquiry prior to its resumption.

13 What is our role? The role of the legal team now 14 that the oral hearings is commenced is, in large part, 15 but not exclusively so, to focus on the evidence, to 16 ensure that the examination of witnesses is rigorous and elicits all of the relevant evidence in a way which is 17 not just fair to the witness and range of views of the 18 core participants, but also bears in mind the public 19 20 interest. It is my duty to act impartially, 21 independently from you, Mr Chairman, and act in the 22 public interest, and the work of the legal team in relation to the evidence has been and is being 23 determined by the Inquiry's revised terms of reference 24 25 and the list of issues that you, Mr Chairman, have

published and which may change from time to time.

1

2 It will be appreciated in what I've said so far about the revised terms of reference that the expansion 3 4 of the Inquiry's work following the addition of the cases of Claire and Conor and the translation of revised 5 6 terms of reference into a published list of issues, that 7 the consideration of issues of such breadth and depth 8 has been a huge undertaking for the legal team and has 9 taken time. Effectively, we have been pursuing five 10 interlinked enquiries or investigations into both clinical and governance matters and it has been my job, 11 12 assisted by the other members of the legal team, to 13 investigate the evidence relating to the issues that 14 arise from the revised terms of reference. That is the 15 first part of our work, which roughly corresponds to 16 what was stages A, document gathering, and C, witness statements, in the original general procedures which 17 were published on the Inquiry's website. 18

19 It has also included obtaining and analysing expert 20 reports, and this has been a particularly taxing 21 exercise where there have been differences of view 22 between eminent experts. Such differences have made it 23 necessary to test and probe not only the underlying 24 assumptions made by the experts but also the clinical 25 and evidential basis of their views. That is a crucial

process and it has been time-consuming. Unfortunately, it is not yet complete and there are outstanding reports from experts on both clinical as well as hospital management and governance matters. They will be issued when received in accordance with the procedures that you have established, Mr Chairman.

7 It is a matter entirely for you, Mr Chairman, what 8 consideration and weight you place on the various forms 9 of documentary evidence that the legal team has 10 presented and will present to you, ranging from the background papers which seek to provide a context to 11 12 some of the matters in question to publications and 13 guidelines that could or should have informed the 14 conduct of those involved, to contemporaneous records 15 and documents that may or may not have been accurately 16 recording what was happening, to statements of those involved and the extent to which they are at variance 17 with each other or with previous evidence on those 18 persons, the reports of various experts, and again the 19 20 extent to which they agree with each other, disagree, 21 are consistent with the contemporaneous materials and/or 22 disagree with views expressed in the statements of those 23 who were actually involved, whether as clinicians or managers. 24

25

And the second part of the legal team's work

requires testing that evidence through the questioning 1 2 of witnesses and experts during the oral hearings. It is my task, assisted by the rest of the legal team, 3 4 to explore the issues during the oral hearings in 5 a probing manner. It is not the task of the legal team 6 to develop any particular theory of what happened or to 7 support any particular version of events. Rather, our 8 objective is to try and get to the bottom of what 9 happened and why and present the evidence to enable you, 10 Mr Chairman, to reach the most informed conclusions possible and thereafter to be able to make 11 12 recommendations directed at improving matters.

Ultimately, Mr Chairman, it will be for you to make determinations and findings on the issues arising out of the revised list of issues in the light of all the evidence. That, of course, is why it is crucial for me and the rest of the legal team to properly adduce for you all of the relevant evidence and to test it in a rigorous and balanced way.

20 So if I just come now to concluding what I have to 21 say, I will say a little bit about document gathering. 22 The call for documents has been ongoing since the 23 resumption of the Inquiry's work. The search for 24 documents, which continues, has and is being informed by 25 guidance from the Inquiry's advisers, from our experts

and from the responses to our requests for witness 1 2 statements. To date, we have received over 140 files of documents, and they include the children's medical notes 3 4 and records. We have reports, scans, X-rays, photographs, correspondence and other documents 5 6 generated by the hospitals and authorities. We have 7 depositions from all the inquests and the reports commissioned by the coroner. 8

9 We have the documents held by all the families and 10 the correspondence and transcripts from UTV. We have statements from the PSNI investigations and the reports 11 12 they commissioned. We have the documents related to the 13 GMC in relation to Jarlath O'Donohoe's case and from the 14 NMC proceedings in relation to Ruth Bullas' case. We 15 have documentation from bodies such as the Department of 16 State Pathology, the National Patient Safety Agency, Blood and Transplant, Royal College of Paediatrics and 17 18 Childcare and many, many more. Correspondence from the DLS providing responses to our requests. Literally 19 20 a huge volume of correspondence.

21 We have also received the histological slides and 22 other materials in relation to some of the children and 23 we have provided those to the Inquiry's experts for them 24 to examine and provide reports. In addition to all of 25 that, we have received numerous publications from our

advisers, experts, witnesses and legal representatives, 1 2 and we have compiled a bibliography of all those publications which is being updated as further 3 authorities are cited. We have also compiled 4 a bibliography of the relevant government and other 5 6 publications in respect of healthcare management and 7 governance that are relevant to the children's cases and revised terms of reference. 8

9 And finally to say a little bit about the background 10 papers, which I've mentioned. The earlier concerns over 11 the content of education and training in relation to 12 fluid management and the incidence of paediatric death 13 in Northern Ireland from hyponatraemia were addressed 14 through commissioning certain background papers and they 15 have been published on the Inquiry's website.

Mr Chairman, you explained the purpose of doing so in relation to education and training in the public hearing on 9 March, and you said:

"The reason for commissioning these papers and then circulating them is that we wanted to obtain a picture of the extent to which nurses and doctors have been taught about hyponatraemia and related issues over the last 30 or so years. The picture, as you will see when the receive the reports, the picture that emerges is a bit patchy, but we wanted to do that because it helps to

set a background against which witnesses can be 1 2 questioned at the oral hearings about the extent to which they were aware of hyponatraemia and what training 3 4 they had received. The Inquiry engaged a Dr Michael 5 Ledwith, clinical director of paediatrics, and professor 6 Sir Alan Craft, emeritus professor of child health to 7 provide a background paper on the training and 8 continuing professional development of doctors in 9 Northern Ireland and the rest of the United Kingdom and 10 the Republic of Ireland by way of comparison over the period of 1975 to 2009." 11

12 Mr Chairman, I do not propose to cite extensively 13 from it, but to draw attention to some points that 14 emerge from it:

15 "Until recently, training was at the discretion of 16 individual lecturers and tutors and Solution No. 18 was a commonly-recommended fluid in paediatrics. 17 Hyponatraemia and syndrome of inappropriate secretion of 18 antidiuretic hormone were understood, but regarded as 19 20 uncommon and there was no agreed protocol for the 21 management of children on intravenous fluids and there 22 were no recommendations for regular electrolyte 23 testing."

24 That is as the background paper has described.25 More recently, though, teaching systems have become

more accountable, curricula have specific requirements 1 2 for the teaching of the management of intravenous fluids in paediatrics. Medical students at Queen's are taught 3 4 the prevention of hyponatraemia in adults based on the clinical resource efficiency support team guidelines and 5 6 alert 22 has specifically referred to the use of 7 Solution No. 18 and they're also taught about the 8 guidelines for the management of children in intravenous 9 fluids. That is where matters emerged from the 10 background paper on doctors' training.

In relation to that of nurses, Professor Mary 11 12 Hanratty, who was the former vice president of the 13 Nursing and Midwifery Council and Professor Alan Glasper, professor of children and young persons nursing 14 15 at the university of Southampton, they were engaged to 16 provide a similar or comparable paper for the training and education of nurses in Northern Ireland, the rest of 17 the United Kingdom and again in the Republic of Ireland, 18 over a period, slightly more extended this time, from 19 1975 to 2011. 20

The main points which emerged from that are that they say that maintaining fluid balance was often part of a pre- and post-registration nurse education programme, but hyponatraemia itself was rarely specifically mentioned. On the whole, there was little

attention paid to the Department of Health guidance on 1 2 the management of hyponatraemia that was circulated in 2002, and that that, they consider, led to the RQIA 3 4 assessment in 2008 finding that changes in practice were 5 patchy, and that every trust has since revised and 6 updated the prescription, administration instructions 7 and fluid intake and output documents, reflecting the 8 efforts to prevent the development of hyponatraemia in 9 children.

10 So that was as far as training went. In relation to your concern, Mr Chairman, with the incidence of it and 11 12 how that compared with the rest of the United Kingdom 13 and, indeed, Europe, the Inquiry engaged Dr David Marshall, who was a senior principal statistician at 14 15 NISRA on child hospital deaths in Northern Ireland from 16 hyponatraemia or fluid overload and compare that with such deaths in the rest of the United Kingdom and 17 Western Europe, and he looked at the period 1979 to 18 2008, initially. 19

The salient points from his work were that there were 111 registered deaths in Northern Ireland between 1979 and 2008, where hyponatraemia or fluid overload was recorded as a cause of death. Of these, 13 were coded as underlying cause of death, none of them were children. For the remaining 98, hyponatraemia, or fluid

overload, is recorded as secondary cause of death and
 five of those deaths were to children aged less than 15.
 That was his first finding.

A second was that initial analysis indicates a higher rate of child mortality in Northern Ireland than in selected other European countries where hyponatraemia/fluid overload is a factor in the cause of death, but he cautions how that should be regarded because he says:

10 "The analysis should be treated with care because 11 there is a small number of registered deaths in 12 Northern Ireland."

13 That's the first thing. He emphasises it's very 14 small:

15 "The fact that the numbers are based on death 16 certificate coding which can vary greatly from country 17 to country and the knowledge and awareness of the 18 condition can also vary from country to country."

19 The difficulties in statistical comparison 20 identified in those background papers were referred to 21 by you, Mr Chairman, at the progress hearing on 22 9 March 2011, and you identified that the issue of 23 concern which was really emerging was that of the coding 24 system for deaths, and a potential problem is the 25 accuracy and reliability of the coding system. Unless

the coding system is accurate and reliable, it doesn't give you, whether in hyponatraemia or any other area, a truly accurate report on the incidence of various conditions, such as hyponatraemia, and the Inquiry has taken that up and is investigating the issue of the coding system in Northern Ireland.

7 Finally, there were two other specialist areas where 8 it was considered helpful to have an appropriate factual 9 context in which to receive and consider oral evidence 10 of witnesses. One of those relates to coroners and the other to post-mortems. So Dr Bridget Dolan was engaged 11 12 on the system of procedures and practices in the 13 United Kingdom for reporting and disseminating 14 information on the outcomes or lessons to be learned 15 from coroners' inquests on deaths in hospitals.

16 I don't, again, want to cite extensively from that, but just to highlight some of the points they made. 17 First, she pointed out that a coroner has the power to 18 report the circumstances of an inquest case to an 19 20 appropriate authority. That's rule 43 in England and 21 Wales; in Northern Ireland it's rule 23. In England and 22 Wales, there is no national procedure or policy for the 23 dissemination of those reports beyond the recipients, and there was no central collation of reports pertaining 24 to healthcare issues by the Department of Health, nor 25

any review of the rule 43 reports. In Northern Ireland, 1 2 there were no central figures for rule 23 referrals. She then went on to say that the amended rule 43 3 power in England and Wales, which came into effect in 4 5 2008, increased the effect of a rule 43 report: 6 "The coroner has a wider remit for issuing them and 7 anyone receiving a report must provide the coroner with 8 a written response which must be sent to the Lord 9 Chancellor and may be published. And the 10 Ministry of Justice now produces regular bulletins collating all rule 43 reports in the previous six 11 12 months."

13 There were and still are no sanctions for failing to 14 respond to a rule 23 in Northern Ireland or a rule 43 in 15 England and Wales.

16 THE CHAIRMAN: Just to spell that out, that means that if 17 for instance Mr Leckey, as the senior coroner, had 18 concerns over Adam's inquest, he has the power to report 19 that to the department. That power has been more 20 developed in England, but neither in Northern Ireland or 21 the rest of the United Kingdom is there a sanction for 22 a failure to respond.

23 MS ANYADIKE-DANES: No, there is not as yet.

The final background paper was from Dr Jean Keeling,the paediatric pathologist. She was asked to provide

a background paper on the system of procedures for the
 dissemination of information gained by post-mortem
 examination following an unexpected death of a child in
 hospital. Some of the key points from her background
 paper are:

6 "Apart from issuing the death certificate, there is 7 no standard practice in the United Kingdom for 8 disseminating the information regarding unexpected death 9 in a hospital to other hospitals and bodies. Likewise, 10 there is no common practice for internal analysis of deaths by hospitals, although many hospitals have 11 12 meetings in which recent deaths are discussed, morbidity 13 and mortality meetings, for example."

But I think what she is highlighting is that there is no standard practice for it:

16 "Coding is performed by clerks in hospitals based on 17 information received from doctors. The likely source of 18 an error in coding is from the doctors involved rather 19 than the coders. Inaccurate coding could affect 20 government-generated statistics."

21 But she thought it was unlikely to affect 22 an analysis such as the national confidential Inquiry 23 into peri-operative deaths, where information is 24 obtained on direct enquiry from consultants.

25 And finally she expressed the view that there are no

formal practices governing the dissemination of information from coroners' inquests to hospitals, trusts and educational establishments. It's not that it can't happen; what she says is there are no formal procedures for doing that.

6 Expert reports, just a little bit about them. The 7 Inquiry engaged experts to provide reports as advised by 8 its advisers to address both general issues, such as the 9 role of certain clinicians, as well as discrete issues 10 such as the interpretation of X-rays and CT scans. The reports of the experts that have been received to date 11 12 in Adam's case have all been made available to the 13 interested parties and further reports, if they are received, will be published in due course. 14

15 The investigation into the cases of Claire, Lucy, 16 Raychel and Conor is ongoing and the reports of the 17 experts involved in those cases will also be made 18 available and published in accordance with your 19 protocols, Mr Chairman.

Then witness statements. The Inquiry has requested and received witness statements and supplemental witness statements, sometimes more than just a single round. The legal team has been guided in its questioning by advisers, the medical notes and records and other contemporaneous material, the subsequent documents

received, expert reports and the previous statements 1 2 made by the witnesses to whichever body and, of course, the statements from other witnesses. The witness 3 4 statements that the Inquiry has sought and received cover the range from those whose involvement in the 5 6 children's case is peripheral, but whose evidence is 7 required to establish some discrete point, to those 8 directly involved, whether in the provision of medical 9 care or in the management and governance of the 10 provision of such care.

It is entirely possible that the evidence provided 11 12 by a witness statement to be sufficient and particularly 13 where it's not contradicted by any other source or challenged and to stand in lieu of oral evidence from 14 15 that person. The legal team has prepared a schedule in 16 the case of Adam of those witnesses that are not being called and whose Inquiry witness statement is being 17 18 tendered as an unchallenged account. Similar schedules will be prepared for each of the other children's cases 19 20 when that time comes.

21 Some, unfortunately, of the witnesses that the 22 Inquiry would wish to call have since died or are too 23 ill to give evidence. For example, the list of persons 24 involved that has been published for Adam's case show 25 that Dr Fiona Gibson is too ill to assist, regrettably

for her. She was the consultant anaesthetist at the Royal Hospital who was asked in December 1995 to review the processes and equipment used in the children's hospitals' operating theatres.

5 In the event that the evidence of a witness is 6 recorded in a statement, whether it is a deposition or a 7 statement to the PSNI or an Inquiry witness statement, 8 such as Dr Gibson's PSNI statement, then Mr Chairman, it 9 will be a matter for you to determine what weight 10 you will afford it in the light of all of the other 11 evidence that you hear.

12 This really is the final thing. You will have 13 appreciated, Mr Chairman, as I have gone through this opening that there have been a number of documents that 14 15 the legal team has compiled. Really, we've done it to 16 assist in distilling what is a vast amount of information accumulated over the time, and some of the 17 18 documents that we have compiled are of general application. For example, the maps showing the 19 positions of trusts and boards, and so forth, and I've 20 21 referred to some of those types of documents in the 22 course of this opening. But some of the documents 23 compiled relate solely to a particular child's case such as the clinical chronologies, and I will refer to those 24 documents at the openings of each of the relevant 25

child's case. The current categories of documents that 1 2 are compiled or are being compiled are set out in an appendix to this general opening, and since the 3 investigations are continuing, it is possible that 4 5 further such documents will be provided. But as it 6 stands at the moment, when this is published, there will 7 be a list of categories that we are working on and will 8 have completed.

9 Mr Chairman, the next thing ordinarily would be to 10 address the issue of the oral hearings. But I know, 11 Mr Chairman, that you wish to deal with that yourself. 12 So unless there is anything further that I can help you 13 with.

14 THE CHAIRMAN: Thank you, Ms Anyadike-Danes, for that very 15 comprehensive analysis of how the Inquiry has come about 16 and what we've been doing with others over the last 17 number of years.

18 What should now have happened and what we said in the past would happen now is that once 19 20 Ms Anyadike-Danes had completed the general opening of 21 the Inquiry, which is what she has done over the last 22 two-and-three-quarter hours, she would move on to give 23 a specific opening to the Inquiry in relation to Adam and the clinical issues arising in Adam's case. 24 25 You know from the report which I circulated last

week from Professor Kirkham and from the note that I then circulated on Friday that there are now problems about that. I want to come back to those after lunch. We'll stop in a few minutes for lunch for approximately one hour.

6 What I want to check is this: that when we were here 7 a few weeks ago, I asked if there were any parties who 8 wanted to make opening statements, and I understand 9 Mr McBrien, that you said you did. Mr Topolski, I think 10 you have said you want to, and Mr Shaw, I have now heard 11 that you have.

First of all, of course, I am quite happy to hear opening statements, but I'm anxious to focus those today on the opening in general statements, not on opening statements specific to Adam clinical. Do you understand that, Mr McBrien? Will you be making such a statement

17 after lunch?

18 MR McBRIEN: That was my intention, yes, sir.

19 THE CHAIRMAN: This is a general opening statement?

20 MR McBRIEN: Yes, sir.

21 THE CHAIRMAN: Mr Topolski?

22 MR TOPOLSKI: Yes, very general -- and about

23 three-and-a-half minutes.

24 THE CHAIRMAN: Even better. Mr Shaw?

25 MR SHAW: It's general. I can beat that. It might take

1 about 30 seconds.

2	THE CHAIRMAN: Is there anyone else who wants to make
3	a general opening statement? Okay. We'll do those
4	immediately after lunch. Mr McBrien, can you give us an
5	estimate?
6	MR McBRIEN: I'd have thought about five or ten minutes,
7	sir.
8	THE CHAIRMAN: I'm not rushing anybody, I'm just asking for
9	time indications. If those are adhered to, it will mean
10	that by 2.30, we will get to the issue which I issued
11	the note about on Friday. We could consider how and in
12	what way the Inquiry can then proceed as quickly as
13	possible to continue with the hearings into the clinical
14	aspects of Adam's treatment. Thank you very much.
15	We'll be back at 2 o'clock.
16	(1.00 pm)
17	(The Short Adjournment)
18	(2.00 pm)
19	THE CHAIRMAN: Thank you. Mr McBrien, on behalf of Adam's
20	mother, Mrs Slavin, and the Slavin family, do you want
21	to make an opening statement?
22	MR McBRIEN: If I may, sir. Shall I commence now?
~ ~	
23	THE CHAIRMAN: Yes.
23 24	THE CHAIRMAN: Yes. Opening by MR McBRIEN

stenographer, my name is David McBrien, counsel for the
 family of Adam Strain, instructed by David Hunter,
 solicitor, of Hunter Associates.

Mr Chairman, on the one hand, I wish to express 4 gratitude on behalf of the family of Adam Strain that 5 6 we have at last reached the start of the substantive 7 hearings. On the other hand, the stress and strain of 8 the unexpected postponement in the autumn of last year 9 has taken its toll on the family. Your determination to 10 have this Inquiry benefits not only the family of Adam Strain, not only the other families represented in 11 12 this Inquiry, but also the local and, perhaps, even the 13 national community.

Although years have passed since the start of this Inquiry, Adam's family understand that it has taken that time to investigate in detail the issues which have arisen. Much information has come to light, many questions have been answered, much has been explained.

19 The amount of time and effort that has been expended 20 is considerable. However, it will have been worth it if 21 lessons can be learned. The truth is what matters. 22 Nevertheless, in examining the documents furnished by 23 the Inquiry, the family has experienced a whole gamut of 24 emotions: amazement, shock, disappointment and anger. 25 Moreover, in common with many others, Adam's mother

has always felt frustrated, annoyed and disappointed by the fact that the Royal Group of Hospitals Trust required her to settle proceedings against them, not only without any admission of liability but also on the basis that, and I quote:

6 "The terms of settlement shall remain confidential 7 and neither party shall disclose to any third party any 8 details concerning the settlement and, in particular, 9 she would not publish, cause to be published, nor 10 provide information in relation to this matter to any third party or make any comment in relation to the 11 12 matter at any time to represent it to the newspapers, 13 television, journals, or any other publicity media."

Neither the trust nor any of its successors have 14 15 released her from this undertaking. It is only in the 16 context of this Inquiry that she is permitted to air her true thoughts and feelings. Part of her is hoping that 17 the Inquiry will be able to ascertain just why this 18 confidentiality clause was required. Are we not 19 20 supposed to be part of an open society? If clinicians 21 or other staff have made mistakes, then does the public 22 not have a right to know?

23 She also feels some despair that it has taken both 24 a political and media campaign to bring these matters 25 out into the open. Why is there such a culture of

secrecy in hospitals? Where does it originate? Does
 openness not encourage better practice? She hopes that
 some of these questions will be answered.

In the press release of 1 November 2004, which is Inquiry document 008-032-093, the minister set out two very important issues, namely, one, that the general public should have confidence in the Health Service and in the standards of performance of all who work in it. And, two, the fact that the death of a child is tragic.

Adam's family agree. His mother, Debra, has put on record that the two reasons she has put herself and her family through the pain of this Inquiry are to find out what really happened to her beautiful only child and also to try to help prevent any other family having to go through what she has.

16 It is therefore important that not only all those involved in this public Inquiry, but also those reading 17 the documents connected there with should remember that 18 it all started with the death of a little four year-old 19 20 boy. He may have been a case, but he was also Debra's 21 son. She has stated that the day he passed away, part of her died too. She will never get over how 22 disrespectfully her little boy was treated. She was and 23 remains hurt by it. Her memories of him have been 24 25 tainted by what happened and the way in which she was

treated right after his death. The inquest and subsequent civil proceedings should have brought closure to her grief. They did not. There was no explanation, just questions.

5 And then to find out that some other children have 6 suffered the same fate concerns her greatly. To have, 7 to hold your child when they die is the worst thing that 8 can happen to any parent. This is not how it is 9 supposed to be. The various issues arising were set out 10 somewhat prophetically in a letter dated 1 May 2002 from the then medical director of the Altnagelvin Hospital to 11 12 Dr Henrietta Campbell, the then chief medical officer. 13 It is Inquiry document 006-002-252.

14 He wrote:

15 "Following the death of a child in Altnagelvin 16 Hospital, which was thought to have followed severe hyponatraemia, many steps have been taken to ensure that 17 18 such an event does not occur again. We are all anxious to learn from what was a dreadful experience and to 19 share vital information with others. Guidance issued 20 21 from your department will help in this regard and we are 22 grateful for the recent posters on the subject. I am 23 interested to know if any such guidance was issued by the Department of Health following the death of a child 24 25 in the Belfast Hospital For Sick Children, which

occurred some five years ago, and whose death the Belfast coroner investigated. I was unaware of this case and am somewhat at a loss to explain why. I would be grateful if you could furnish me with any details of that particular case for I believe that questions will be asked as to why we did not learn from what appears to have been a similar event."

8 If families can be assured both that lessons have 9 been learnt and that changes will be made, then it may 10 ease their grief and give them both solace and closure.

Finally, Debra would like to adopt the minister's words: I am grateful to John O'Hara for agreeing to undertake this Inquiry and I know that he will pursue a rigorous investigation of the issues. Thank you.
THE CHAIRMAN: Thank you, Mr McBrien. Mr Topolski?
Opening by MR TOPOLSKI

MR TOPOLSKI: Sir, thank you for inviting and permitting us to make a very brief statement on behalf of the Ferguson family. I wonder if we could please put up a photograph of Raychel.

21 But for the treatment Raychel received at the 22 Altnagelvin Hospital in June 2001, she would have lived. 23 The neurological insult she suffered and which killed 24 her was a result of hospital-acquired hyponatraemia. 25 The insult was the result of the administration of

hypertonic infusions, specifically Solution 18. Those
 three facts have been, we suggest, clearly established,
 not least by the inquest verdict recorded
 in February 2003.

5 The consequence of those three facts have haunted 6 and blighted the lives of her parents, her family and 7 her friends, and will continue to do so. Every day, 8 sir, Raychel's mother goes to her daughter's grave. 9 Every day. She has promised her countless times that 10 she and her family will not rest until they discover what led to this tragedy. In its brief to its experts, 11 12 this Inquiry observes that it was a UTV insight 13 documentary called "When Hospitals Kill", broadcast in 2004, that was the impetus for this Inquiry. 14

15 At a time when journalism in all its forms is under 16 the most intense scrutiny, it is right that an example of journalism at its most forthright should be 17 acknowledged. But it is not a chilling, eye-catching 18 title, it's not the assertions made in a TV programme 19 20 that will enable Marie Ferguson to fulfil her promise to 21 her daughter. It is and can only be the evidence that is received, sir, by you, examined, tested and 22 23 finally pronounced upon by you that can do that.

24 The great institutions of state are a measure of its25 strength and of its resilience. The National Health

Service is one such institution. When events such as 1 2 those that are the subject matter of this Inquiry occur within them and with such devastating consequences, 3 4 it is a measure of the true strength and greatness of the institution concerned that it is prepared to expose 5 6 itself to the most rigorous and fearless examination. 7 All our clients can ask is for this Inquiry to carry out 8 that examination rigorously and fearlessly. They have 9 every confidence it will do so because, bluntly, nothing 10 less will do. Our clients, we their legal team -- and forgive me for not introducing myself, I'm Michael 11 12 Topolski, I'm instructed by Mr Desmond Doherty and 13 leading Mr John Coyle -- we are ready, as indeed are our 14 clients, to let the evidence speak. The task and duty 15 of this Inquiry, we suggest, is to follow wherever that 16 evidence leads.

17 May I just conclude this opening with three lines, 18 not of mine -- much better than mine -- they're from my 19 client in a statement she made and sent to this Inquiry 20 this very weekend:

"We can never bring Raychel back, but we owe it to her to make sure that the way she died cannot be repeated. The path to this Inquiry has been a long and agonising one for myself and my family. We will not rest until we have fulfilled this promise to the

daughter we love and miss to this day."
 Thank you.
 THE CHAIRMAN: Thank you very much, Mr Topolski. I think

4

Mr Shaw ...

5 Opening by MR SHAW 6 MR SHAW: Mr Chairman, my name is Stephen Shaw, senior 7 counsel for the department. Thank you for the 8 opportunity to make this statement.

9 The death of a child brings great pain and distress 10 to the bereaved family. The department wants to extend, 11 once again, its profound sympathy to all those who mourn 12 the loss of a child under investigation by this Inquiry.

13 This Inquiry was set up on 1 November 2004 by Angela 14 Smith MP, the minister then responsible for health and 15 personal social services in Northern Ireland. She and 16 her successors, including the present minister, Mr Poots, have made it clear that they want this Inquiry 17 18 to address the issues of public concern raised by these tragic deaths and to make recommendations, as you may 19 20 consider necessary and appropriate.

The department welcomes the fact that the Inquiry has now started. We are confident that this independent Inquiry will be rigorous and comprehensive in performing its task. We look forward to the opportunity to play our part and to respond in due course. The department

1 remains committed to protecting and improving the 2 quality of health and social care so that all the people 3 of Northern Ireland might benefit from a safe and 4 effective service.

5 The department recognises that the public must have 6 confidence in the safety, quality and standards of care 7 provided by our health and social care services. We 8 will, therefore, assist the Inquiry as fully as we can 9 and with total commitment to openness and transparency. 10 Thank you, sir.

11 THE CHAIRMAN: Thank you, Mr Shaw.

12 Now, ladies and gentlemen, let me turn to the issue 13 which you were notified of last week, in particular the 14 report that was circulated from Professor Fenella 15 Kirkham, a neurologist, and the note which I issued on 16 Friday.

There is nothing new in this Inquiry or any other 17 Inquiry about expert witnesses expressing different 18 opinions. We already have examples of differing views 19 20 in this Inquiry. For instance, about who should have 21 taken the consent from Adam's mother for his kidney 22 transplant or what the consequences are or may be of 23 certain uncertain aspects to the medical treatment. And we were ready to proceed without necessarily having 24 25 unanimity between the experts because the Inquiry cannot

possibly wait until we have unanimity before we start. In fact, it would be quite wrong to try to extract unanimity from experts with different views and what we'll hear in the weeks and months ahead are those different views and the impact those different views have on the opinions which have been formed about the actions and conduct of certain individuals.

8 The difficulty which Professor Kirkham's report 9 raises is a rather different one. She has substantially 10 queried whether Adam died from hyponatraemia at all. This is an issue about which there has been only very 11 12 limited debate since the inquest into Adam's death. 13 I think it's right to say that, apart from Dr Taylor, no other person has held out against hyponatraemia at least 14 15 being a contributory factor to Adam's death, if not the 16 dominant factor. And even in his recent statement to the Inquiry, in which Dr Taylor accepted that in some 17 respects his care of Adam was below expectations, he did 18 not move away from his position and he did not expressly 19 20 say that hyponatraemia had caused Adam's death.

I regret more than I can express the fact that Professor Kirkham's report has come through so late. You will recall that the hearings which were scheduled to start last November were delayed because, as I informed everyone at the time, I had received advice

1 from the medical advisers to the Inquiry that, in the 2 light of the ever-increasing volume of medical opinion 3 and documentation, it was necessary to obtain the views 4 of a neurologist.

5 That was put in train and Professor Kirkham was 6 asked to report to us. Her report was delayed by what 7 turned out to be the complexity of the issues, by her 8 request for further information and then by her request 9 for further reports from Dr Squier, such as the note 10 which is attached to the report circulated last week.

11 Now that that has been received, it seems to me that 12 there are two issues which we have to consider this 13 afternoon. The first issue is whether we can proceed 14 immediately with the scheduled hearings next week. The 15 second issue is: if we cannot proceed next week, what do 16 we do next? When do we start the hearings and how do we 17 start them?

18 On the first point about whether we can start next week, you will understand from the note which I issued 19 20 on Friday that I think that everyone needs some time to 21 consider Professor Kirkham's report because, within it, 22 she raises queries which simply have to be addressed and 23 which I do not think can be simply addressed by her coming into the witness box either at the start of the 24 oral evidence or later on in the oral evidence. 25

Perhaps more fundamentally, the basis upon which 1 2 witnesses are to be questioned is affected or may be affected by her conclusions. For instance, it is not 3 4 clear from her report whether or to what extent she calls into question the care which Adam received from 5 6 different individuals in 1995. Nor is it clear from 7 this report what she says should have been recognised in 8 1995 as opposed to today because those of you who have 9 had time to study her report will have noticed that she 10 talks about the fact that there is better neuro-imaging available today than there was in 1995, and she has also 11 12 said that there is much greater awareness of PRES and 13 its risk factors today than there was in 1995.

Issues such as these all have the potential to alter the contents of the Salmon letters, which I was to issue last week, but which I withheld when I was alerted to the fact that Professor Kirkham was likely to come through with some substantially different positions.

And for those of you who are not immediately familiar with what a Salmon letter is, a Salmon letter, in effect, is a guarantee of fairness that means that before any individual, for instance a doctor or a nurse, comes to give evidence at the Inquiry, that doctor or nurse is put on notice of any particular issues on which he or she will be questioned and probed about the

actions which they took and whether those actions were
 up to standard by the standards of the time.

We had clearly identified areas of questioning on 3 4 the basis of all of the documentation which Ms Anyadike-Danes referred to in her opening address 5 6 this morning. In particular, we had identified areas of 7 questioning based on the reports from experts such as doctors Coulthard, Haines and Gross. What we now need 8 9 to know is what, if any, additional or different 10 questioning witnesses might face on the basis of Professor Kirkham. Is there to be a new line of 11 12 questioning or probing?

13 In this context, I should also say that on behalf of 14 Adam's family, his solicitors and counsel provided us 15 with warning letters -- effectively the equivalent of 16 Salmon letters -- in which they identified areas upon which they thought witnesses would have to be questioned 17 18 and potentially criticised. It seems to me that in light of Professor Kirkham's report, Adam's family's 19 20 legal representatives will have to consider whether they 21 want to add to or alter their warning letters for the 22 same reason.

In addition, I think it's inevitable that the consultants and others who are going to face questioning will want a little time before they give evidence in

order to allow them to appreciate what flows from
Professor Kirkham's analysis for each of them, and they
will, for instance, want to think through what the
consequences are of what Professor Kirkham says as
opposed to what various other experts have said, to see
whether that potentially adds to or takes away from any
potential criticism which they will face.

8 Subject to whatever anyone says to me over the next 9 few minutes, I think that the first issue which I have 10 identified, namely whether the scheduled hearings can start next week, is fairly straightforward. Even though 11 12 it is massively disappointing for me to say this at this 13 stage, I do not think that the hearings can resume next 14 Monday with the start of the oral evidence. I will 15 invite observations on that in a few minutes.

16 Let me then turn to what I've identified as the second question. If we don't start next Monday, when do 17 we start and what do we have to do in between? In the 18 note which was issued last week, I have outlined the 19 20 process which I propose to follow -- again, subject to 21 anything that is said to me in the next little while --22 and we follow that process in the next week or week and 23 a half in order to minimise the delay and start the hearings as soon as is ever possible. 24

25 I cannot contemplate a long delay and I say that not

just for my own reasons, but also because I understand that for Adam's family, for Claire's family, for Raychel's familiar and for Conor's family, the thought of further delay, stretching out indefinitely into the future is just beyond contemplation.

6 I also recognise that there are other people who 7 want the Inquiry to proceed sooner rather than later. For instance, those individual consultants who have been 8 9 under scrutiny and who know they are going to face 10 probing and potential criticism must surely want that to take place as soon as possible so that they have the 11 12 opportunity to say whatever they want to say to the 13 Inquiry in order to have their actions and conduct properly understood. 14

15 But there is, beyond that, an even more important 16 reason for progressing sooner rather than later. That reason is that one of the fundamental values of this 17 Inquiry is that if there are lessons which have not yet 18 19 been learned and if there are things which can be done 20 better in the future, the sooner that is recognised and 21 the sooner those lessons are learned the better, and 22 that may come eventually from my report to the minister. 23 It may also come from people who are involved in the clinical world or involved in the management and 24 governance of the Health Service, hearing what has taken 25

1 place at the Inquiry and starting on their own 2 initiative to take steps to improve arrangements and 3 improve management without waiting for any report which 4 comes from me.

5 The efforts which we are making on the back of the 6 report from Professor Kirkham are to try to convene 7 a meeting, which Professor Kirkham will attend with 8 a number of the other expert witnesses to the Inquiry. 9 We have provisionally arranged such a meeting in 10 Newcastle, England, this Wednesday evening. Professor Kirkham can attend that. The simple reason 11 12 why it might be in Newcastle is that Mr Coulthard and 13 Dr Haines are based in Newcastle and they can attend such a meeting. We can also arrange for Mr Gross, from 14 15 Germany, and I think Dr Squier, who's based in Oxford, 16 to phone into that meeting. So there will be a meeting of experts. If we can arrange for any of the other 17 expert witnesses to the Inquiry to attend either 18 personally or by phone, then we will. 19

The point about that, as we have explained in last Friday's note, is to clarify the extent, if any, to which the experts agree with each other and whether they each maintain or reconsider their position in the light of the contribution of the professor. It might be, for instance, that Messrs Coulthard and Haines say: well, we

weren't entirely aware or as aware as Professor Kirkham 1 2 is of the advantages of neuro-imaging now or the risks associated with and the potential for the development of 3 4 PRES and we want to reconsider our advice and our evidence to the Inquiry in that light. It might also be 5 6 of course that they say: actually, we were well aware of 7 it, but it doesn't make any real difference to our 8 report.

9 What we are trying to achieve is having this meeting 10 on Wednesday. It'll be preceded, if our plan comes to fruition, with the other experts other than 11 12 Professor Kirkham giving us an initial written response 13 to Professor Kirkham's report. The value of that is 14 that it will enable Professor Kirkham to understand and 15 for those other experts to understand, before they meet, 16 how far apart they are and, if they are apart, what the basis of them remaining apart is. 17

18 Following on from that, we will try to have a record produced. Certainly, we will have a record produced of 19 20 that meeting. We are considering whether the meeting 21 can be recorded or, at the very least, transcribed so 22 that instead of having to rely on a record prepared by 23 the Inquiry legal team who will attend the meeting, we will be able to provide some form of transcript or 24 recording of it so that those who have different 25

interests can see how the discussion and conversations
 developed during the meeting.

I would then propose, after the meeting, to allow 3 any of the experts a short time -- by which I mean just 4 a few days -- to add anything in writing, which they 5 6 feel they want to add in light of the discussions. 7 There may, for instance, be an expert who is in 8 discussion at the meeting and some point occurs to him 9 or her which he then wants to follow up with a written note afterwards. That's the sort of thing I'm trying to 10 achieve. So not only is the Inquiry better informed, 11 12 but everybody is better informed.

13 Following on from that, on this proposal, which is the proposal I'm throwing out to debate in the next few 14 15 minutes, I would like to reconvene here on Thursday 16 next -- I think that's Thursday the 30th -- to give you an update and give you all an opportunity to express 17 your views on how we should or might proceed after that. 18 We were due to be here next week anyway and therefore 19 20 a reconvening on Thursday the 30th would not be, 21 I think, too much of a call on anyone.

It will have two consequences. The first is that because I would have circulated all of the available additional documentation in advance of that, you'll be able to come to that meeting with a clearer idea of

1 where the experts stand and perhaps your own ideas of 2 how we can move forward.

3 Secondly, we can then discuss how and when the 4 evidence could start and the specific opening in Adam's 5 case might be made after that.

6 That is my proposal. It is inevitably outside the 7 scope of the procedures, which I've already outlined, 8 and I hope it's understood that it is outside the scope 9 because the position we've reached in light of this late 10 contribution from Professor Kirkham is something which could not have been contemplated or provided for in the 11 12 procedures. The only other point, of course, about the 13 procedures is that I have always specifically retained discretion to vary the procedures if needs be, if 14 15 circumstances dictate it, and I don't really think there 16 can be any dispute that the circumstances are dictating some change to the procedures immediately, whether it is 17 the change which I'm proposing is a matter which we can 18 discuss. 19

That's all that I think I want to say just at the moment. I think, perhaps, I'd like to break down the discussion into two separate parts. The first part is this: is there any representative who wants to contend that, notwithstanding the issues that I've gone through, that the hearings should resume next Monday the 27th?

I Is there any party who adopts that position that we should start next Monday?

MR MILLAR: Sir, my name is Robert Millar, counsel for 3 4 Mr Patrick Keane. I am instructed by Carson McDowell 5 solicitors. My instructions certainly extend to that 6 proposition, that one option which should be actively 7 considered by the Inquiry is continuing. We have serious reservations about the usefulness of the 8 9 procedure that's being envisaged by the Inquiry. I don't know whether it's better to develop the point 10 11 in the context of overall remarks or whether you --12 THE CHAIRMAN: I'm keen to know how we could proceed next 13 Monday.

14 MR MILLAR: As we see it, if I could just preface this by 15 saying this. My client, Mr Keane, is one of three 16 neuro-oncologists in Northern Ireland. In November, he absented himself for five weeks with a huge knock-on 17 18 effect on his operation list. He has done the same for the Inquiry this time; he has taken a further five weeks 19 20 away from that post. And therefore, for that reason 21 alone, we're very keen that the Inquiry should proceed as soon as possible. Now, the question is: what is "as 22 23 soon as possible"?

24 The contribution that's been made by25 Professor Kirkham, as you said, sir, has come at a late

stage. I think that's one of the issues we'd want to touch upon slightly. My note of the hearing back in October of last year relating to the postponement of the Inquiry at that time includes an indication by you that you had been advised by some of your expert advisers that there were two further reports required in areas that were central to Adam's case.

8 Obviously, I'm not familiar with the ins and outs of 9 all the other cases, but in Adam's case you have a child 10 who developed cerebral oedema. Certainly, we find it surprising, sir, that your advisers had not indicated at 11 12 a much earlier stage that a neurologist, who would seem 13 to be the most appropriate expert to advise in relation to a case of cerebral oedema, had not been retained as 14 15 an expert witness by the Inquiry at a much earlier 16 stage. I appreciate that clearly you, sir, are very much at the mercy of the expert medical advice that you 17 18 receive. But one would have thought that in a case of that sort, it would have been fairly obvious to the 19 20 Inquiry's advisers that a neurologist should be part of 21 the expert team.

22 THE CHAIRMAN: Was there a neurologist at the inquest?
23 MR MILLAR: I'm not sure there was.

24 THE CHAIRMAN: As a matter of fact, there wasn't. And when 25 the expert statements were issued by the Inquiry

in October, did your client, or for that matter, any 1 2 other party in this Inquiry come back and say: you can't be serious, you don't have a neurologist? No. For the 3 record, Mr Millar, not one person did. 4 5 MR MILLAR: I accept that entirely for the record. What I'm 6 saying, sir, is in a case involving cerebral oedema one 7 might have thought that the experts advising the Inquiry 8 would have suggested that that expertise should be 9 obtained at an earlier stage. And the same applies to 10 Dr Squier, who is the neuropathologist -- who I understand as the second -- that was the second 11 12 outstanding report as of October 2011. 13 THE CHAIRMAN: No. I think you should actually know from the papers that Dr Squier was already engaged 14 15 before October 2011. 16 MR MILLAR: Was it the neuroradiologist then, sir? Am I misunderstanding? 17 THE CHAIRMAN: Mr Millar, I'm not going to get into 18 19 discussions. I have deliberately avoided telling the 20 parties which experts have been retained or even the 21 speciality in which they've been obtained because I did 22 not want that information to be commonly known before 23 I received back reports from experts. Okay? MR MILLAR: I appreciate that. We did enquire at the time, 24 25 sir, and you did give us that response.

1 THE CHAIRMAN: And it stands.

1	The characteristic and the scanas.
2	MR MILLAR: In any event, one has to then ask at this stage,
3	if we were to have a meeting involving
4	Professor Kirkham, there seem to be three sort of
5	obvious possible outcomes of that. One is that
6	Professor Kirkham may change her mind, and I suppose
7	that would be a significant development. The second
8	is that the others may change their minds, and if that
9	were to happen there would be, one would have thought,
10	fairly fundamental consequences for the Inquiry.
11	I think you said yourself in your note, sir, the
12	very inclusion of this case in the Inquiry is based on
13	the premise that for Adam, the cause of his cerebral
14	oedema was hyponatraemia. I think it's in the fourth
15	paragraph of your note:
16	"The belief that he died of hyponatraemia is
17	fundamental to his death being included in the Inquiry
18	in the first place."
19	THE CHAIRMAN: Yes.
20	MR MILLAR: Obviously, if there is now a serious question
21	mark as to whether that was the cause of death, one has
22	to ask where we go from here. Is it a matter of the
23	entire case being referred back to the coroner, for
24	example? In the other cases that I'm not so familiar
25	with, might there be similar questions raised at this

late stage by someone like Professor Kirkham in relation
 to the cause of death of any of the other children?
 Leaving Conor aside for the moment, where it doesn't
 apply. Has a neurologist been retained in connection to
 the other deaths? I assume that Professor Kirkham is
 dealing only with Adam.

7 THE CHAIRMAN: I think this is your second, if not your 8 third, effort to get me into a discussion over what 9 experts are being retained in other cases or Adam's 10 case. I'm not getting involved in that. I'm intrigued by the idea that if you're now suggesting that this 11 12 raises issues about whether Adam's case should be 13 referred back to the coroner, you're nevertheless 14 submitting that the oral hearings should start next 15 Monday.

MR MILLAR: It is a question of what can usefully be done this week. One can see very readily that one needs to digest what Professor Kirkham's had to say. At this stage, I have no idea whether Professor Kirkham's report has been circulated to the other experts --

21 THE CHAIRMAN: It has.

22 MR MILLAR: -- whether any of them have commented at this
23 stage --

24 THE CHAIRMAN: Not yet.

25 MR MILLAR: -- whether any of them consider themselves

1 qualified to comment.

2 Quite often, when you have a meeting between experts, what you're doing is putting together people 3 4 with different expertises, so the surgeons will speak to 5 the surgeons, the nephrologists to the nephrologists. 6 So far as I know, she is the only paediatric neurologist 7 or the only neurologist of any sort who's involved in 8 the case. So one wonders what she's usefully going to 9 discuss, say for example with Professor Forsythe or 10 Mr Rigg who are surgeons.

11 It's probably less clearly so when it comes to the 12 nephrologists and the anaesthetists, but she is a very 13 specialised person as one can see from her CV and from 14 her report and one has to wonder what level of 15 discussion can take place between her and persons who 16 come from entirely different disciplines and 17 specialisations.

So it may be that a very brief exchange between the experts would result in the other saying: look, we're just simply not in a position to have a useful dialogue with Professor Kirkham because she's a neurologist and we come from entirely different disciplines. It may then be a matter of whether a second neurological is to be obtained.

25 THE CHAIRMAN: In that event, it'll be a very short experts'

1 meeting.

2	MR MILLAR: But one wonders, sir, whether they need to have
3	a meeting to have that level of communication with one
4	another. As I understand it, everything that has
5	happened to date between the Inquiry and the experts has
6	been done on paper. I've certainly seen many follow-up
7	requests for information, obviously drafted by the
8	Inquiry's legal team, asking for questions, probing
9	various questions in an entirely appropriate manner.
10	And one wonders why a similar procedure could not be
11	adopted on this occasion, which may foreshorten the
12	period of delay in getting on with the oral hearings.

But I think, sir, that our main concern is the 13 14 overwhelming likelihood is that if there is a meeting or 15 exchange of views, there will remain important disagreements between the experts and the quicker we 16 move to having those different positions articulated 17 18 publicly so they can be probed in public, the better. 19 THE CHAIRMAN: I don't disagree with you to this extent, Mr Millar, that I would be astonished if the outcome of 20 21 the meeting of the experts was that they all suddenly agreed. But what I think would be valuable to know 22 would be the extent to which, if any, the other experts 23 24 conceded that Professor Kirkham might be right or the extent to which she considered that they might be right. 25

In other words, do they rule out her analysis 1 2 entirely or do they accept that this raises another possibility in a very complex case? And I think that 3 4 it would be very helpful to know that before the questioning of witnesses starts. Because when people 5 6 like your client or Dr Taylor or Professor Savage are 7 giving their evidence, they will want to know the basis 8 upon which they're being questioned. And it might 9 ultimately be that they have to be questioned on the 10 basis that (a) he did die of hyponatraemia or (b) on the basis that he didn't. 11

What we don't quite have in Professor Kirkham's report is, although she's given an alternative cause of death, it's not at all clear from that whether she says that that represents any blameworthiness on the part of any of the individuals. Is that not an issue which we would want to know?

MR MILLAR: That's the type of issue that might be best 18 19 followed up, sir, by a written Inquiry of 20 Professor Kirkham rather than it being between experts 21 and it's difficult to foresee how long it's going to take her to express those views. I accept that. 22 I accept that entirely. But what one has to foresee is 23 this: if the meeting does have the type of outcome that 24 25 you have indicated may well be the most likely outcome,

and that is that there is only some limited agreement or
 Professor Kirkham seems to have fixed her guns, so to
 speak, where does the Inquiry go then?

You are then left in the position then where you 4 5 have one paediatric neurologist, whose opinion is going 6 to carry a considerable amount of weight, one would have 7 thought, in diagnosing a cause of cerebral oedema in 8 a child, ranged against a number of other people whose 9 disciplines are not really precisely that. Is the 10 Inquiry not then going to be forced to either just go with her view because she is the expert who's been 11 12 retained by the Inquiry specifically in that area or do 13 you have to contemplate a second neurologist, a third 14 neurologist? Where does one go? 15 THE CHAIRMAN: I don't think we're going to run down the 16 list of neurologists in the UK or beyond, Mr Millar. MR MILLAR: I appreciate that what I'm saying is actually 17 18 not directed specifically to your point about whether we say that there shouldn't be some postponement. I don't 19

20 think we would suggest for a minute that there shouldn't 21 be any window of time given to allow some of these 22 issues to be explored, and I appreciate that many of the 23 things that I've said point towards there being 24 a window. It's just how one goes about it and perhaps 25 I can be allowed to come back to that when we deal with

1 the issues of procedure.

2	THE CHAIRMAN: I think Mr Millar was the only one that
3	wanted to speak on the question of whether the hearings
4	should not go ahead on Monday 27th. Then let's go on to
5	the second issue, which is the proposal which I've set
6	out in the note on Friday, which I have just added to
7	over the last few minutes with we will have this
8	meeting of as many experts as are available, hopefully
9	on Wednesday evening. We will have a record or minute
10	produced of that, and we will also try to have
11	a recording of it, whether an audio recording or
12	a stenographer, whichever can be arranged. And then
13	report back, circulate back whatever documentation
14	emerges from that and then report back with a progress
15	hearing next Thursday, Thursday the 30th.
16	Sorry, 1 March. Thursday, 1 March. Okay.
17	Mr McBrien, do you want to go first on this?
18	MR McBRIEN: On which particular point, sir?
19	THE CHAIRMAN: I have outlined a possible way forward to try
20	to deal as quickly as possible with the circumstances.
21	MR McBRIEN: We're in agreement as regards the meeting.
22	We're in agreement as regards some form of recording.
23	On the issues of transparency because I'm sure it's
24	anticipated or realised between the parties that it'll
25	be in the interests of some but not the interests of

others, depending upon which way one's views may go.
Therefore, if a particular expert witness were to be
seen to change his or her opinion, and that result
simply being formulated in a minute, then it would leave
matters up in the air and issues could arise there from.

Accordingly, from our perspective, we wholeheartedly support the recording aspect and we would hope that it was a bit -- if it could be a bit more advanced than a pure transcription because whilst a transcription is helpful, it is sometimes better if one can actually get the flavour of what's taking place.

12 THE CHAIRMAN: I entirely agree with that because then you 13 get the impression of nuances or delays or hesitations or whatever. I cannot guarantee that, Mr McBrien, but 14 15 I will make enquiries about if and how that can be done. 16 MR McBRIEN: I think that's all we can ask for. THE CHAIRMAN: Then reporting back, circulating, hopefully 17 18 by next Monday, all available documentation, and reviewing matters next Thursday, the 1st? 19 20 MR McBRIEN: Yes, sir. Just one logistical thing has 21 crossed my mind, and one would wish the experts, when 22 they meet, to be relatively fresh. You may or may not 23 be aware from the papers, sir, that one of the key issues in the Adam Strain case was the fact that the 24 25 clinicians themselves were tired at the time of the

1 surgery.

2	THE CHAIRMAN: Yes.
3	MR McBRIEN: If it's to be an evening session, it may be
4	a short matter, it may be a long meeting, but I don't
5	know how important Professor Gross will be to the
6	affair, but it should be remembered if he's phoning from
7	Germany, they're one hour ahead.
8	THE CHAIRMAN: As I understand it, the provisional
9	arrangement, which has not been confirmed, pending this
10	afternoon's hearing, is that it should be at 6 o'clock.
11	MR McBRIEN: That'll be 7 o'clock for
12	THE CHAIRMAN: It will be. There are some people who are
13	not available at all during the day because they have
14	other commitments or are working. Some of the experts
15	are retired from practice, some are still working.
16	We are trying to get the earliest possible time for
17	exactly the reason you suggested.
18	MR McBRIEN: That's extremely helpful, sir.
19	Then if there could be feedback in that period by
20	Thursday 1 March, that would be helpful because we could
21	then review in fact, all parties I'm sure can review
22	the feedback. Each party has its own particular agenda
23	and we might be looking for different issues. But
24	Thursday 1st seems to be, on the one hand, sufficient
25	time for somebody to produce something and at the same

time to give people a chance to consider it.
 THE CHAIRMAN: Right.

3 MR McBRIEN: So I would support that, sir.

THE CHAIRMAN: Okay, thank you very much. Mr Quinn?
MR QUINN: My name is Stephen Quinn. I appear for both the
Roberts family and the Mitchell family. I appear with
Mr McCrea in the case of Claire Roberts and I have
already given my junior's appearance in the other case.

9 I didn't make an opening statement. I didn't want 10 to waste any more time because time is of the essence here. Both the families, I spoke to them, and they 11 wanted to emphasise two things. They wanted to say very 12 13 briefly how much they appreciated lead counsel for the 14 Inquiry opening the case very directly and very 15 succinctly. They also wanted to express appreciation to 16 yourself for you trying to get on with the case as quickly as possible. They wanted me to make two or 17 18 three points in relation to this delay.

19 They've been waiting a long time. Mr and 20 Mrs Roberts waited -- not only did they wait for 21 everything else, they've waited 10 years for the inquest 22 and they're waiting again. There's been delay of 23 15.5 years since Claire Roberts died. Conor Mitchell's 24 mum, Joanna, has been waiting nine years. What both 25 these families wanted from this is they wanted to see

1 what went wrong with the system. So in a way, the 2 report that we've just had from the professor is not of 3 great relevance to them.

4 What they want to do is they want to move this case 5 on as quickly as possible, but they both recognise that 6 they want to get at the truth, and one of the issues 7 that you raised yourself, Mr Chairman, was that someone 8 may want to ask the question on behalf of the Inquiry 9 team as to what went wrong with the system and that 10 hasn't been addressed in Professor Kirkham's report. Because at the end of the day, what they want to do, 11 12 these families want to ensure that this does not happen 13 again. So in a way, I've been allowed my opening 14 address in a roundabout way and I have already made the 15 point that they don't want any delay that is 16 unnecessary. They see that this has to happen. THE CHAIRMAN: It's particularly relevant to Mr and 17 18 Mrs Roberts.

19 MR QUINN: It is.

20 THE CHAIRMAN: Because if Adam died of hyponatraemia and 21 Claire died of hyponatraemia, what was learned or 22 what was missed, if anything, in the Royal between 1995 23 and 1996 --

24 MR QUINN: Exactly.

25 THE CHAIRMAN: On the other hand, if Professor Kirkham's

right, and Adam did not die of hyponatraemia, it changes -- it obviously doesn't mean that things may not have gone wrong with Claire, but to some extent it may change the prologue to Claire about what was -- was there something missing that might not have been missed and so on?

7 MR QUINN: I didn't want to get into the same field that 8 Mr Millar got into because I didn't want the same 9 response from you, Mr Chairman. Therefore, I didn't 10 want to ask the question about what experts were going to be employed, but I expect that there will be a very 11 12 thorough enquiry into both Conor's and Claire's case and 13 the proper experts will be involved. I do see the link 14 between Claire's case. I don't want to delay it any 15 more, save to say that both the families want this case 16 to commence as soon as possible.

17 One last point, Mr Chairman, there has been some 18 time left aside in various weeks where there have been 19 rest weeks, so perhaps we need to look at using some of 20 those weeks.

THE CHAIRMAN: Well, thanks for raising that. There's a particular period -- we've got a start date, which is today, and we've got an end date, which is November. I should make it clear now that as far as I'm concerned, at the risk to everybody's diaries and holidays,

including my own, as far as I'm concerned, whatever
 happens, we will hit the end date.

If things were moved about so that -- for instance 3 4 there's a 10-week summer break, which wasn't actually 5 a 10-week summer break, so if I have to eat 6 substantially into that because we start something late, 7 I will do that, and I will change whatever -- I will be 8 as flexible and accommodating as I can between now 9 and November. But I have to finish this in November for everybody's sake. Okay? 10

MR QUINN: I'm very grateful for that indication because that's what the families want. They both want this case to go on, they want to see justice done. They want the system to be explored as much as we possibly can, but we want to finish.

16 THE CHAIRMAN: Yes, thank you, Mr Quinn. Mr Topolski? MR TOPOLSKI: Sir, could I make one or two I hope practical 17 18 suggestions? Where, in the jurisdiction with which I'm 19 most familiar, there are a number of experts about to 20 give evidence in a criminal trial, there are now 21 routinely experts' meetings. So we have quite a bit of experience over in England of these, as I imagine you do 22 23 here in some respects.

24 THE CHAIRMAN: We do. I don't want to get into the area of 25 negligence cases, but if there was a medical negligence

case in the High Court, the protocol now is that the 1 2 experts must meet in advance. It's not optional. MR TOPOLSKI: Exactly, so we are familiar. May I then 3 4 commend from, no doubt, those meetings, sir, which with you are familiar and your counsel will be familiar, this 5 6 by way of a suggestion? One of the things that gets 7 experts focused is if there can be some focused questions formulated before the meeting starts in order 8 9 that the experts can consider what they may be. May 10 I give you but one example, and I'm prepared to put it in writing if it will help, but it'll be on the 11 transcript now, for the saving of time. 12

13 It seems to us that one of the very interesting 14 things that Professor Kirkham does not deal with is what 15 the consequence was on Adam of the infusion into him of 16 significant quantities of fluid. Let me tell you exactly what I mean. The blood volume in a child is, as 17 we understand it, 18 mils per kilo. Adam weighed 18 20.2 kilos. He was given at least 1,500 mils of 19 dextrose saline, so there's very nearly a 100 per cent 20 21 dilution of his blood volume.

22 Question, Professor Kirkham: what effect, if any, 23 could that have on the reversibility of the syndrome you 24 identify? For she describes the syndrome, doesn't she, 25 as a reversible syndrome, which means, as we understand

it, that it could be reversed, but wasn't in Adam's 1 2 case. Could it not have been reversed perhaps because he had infused into him -- my phrase, maybe nobody 3 4 else's -- significant quantities of, effectively, water? 5 That's a simple question. It may permit a very simple 6 answer, "That's the most ludicrous question I've ever 7 been asked", but nonetheless it arises. That sort of 8 thing. There are others one can consider, reading her 9 report, but if there were some focused questions, it 10 might assist. THE CHAIRMAN: In that particular question, it's saying that 11 12 it might be that her analysis is correct, but that 13 doesn't mean that Adam's death does not result in 14 hyponatraemia. 15 MR TOPOLSKI: You have my point. Did his infusion aggravate 16 the condition that she has uniquely, in this case so far, identified? Again, a very simple question; there 17 may well be others. Sir, that is the only contribution 18 we want to make. We would urge, again from experience, 19 20 a recording of the meeting. 21 THE CHAIRMAN: I'll do my best. Thank you very much. 22 Mr Lavery? MR LAVERY: Just for the benefit of the stenographer, my 23 name is Michael Lavery. I am junior counsel instructed 24

25 by the directorate of legal services and I appear for

the various hospital trusts, alongside Mr Gerry Simpson
 QC and Mr Gerry McAlinden QC.

Could I just say, Mr Chairman, that we do welcome 3 4 the commencement of the Inquiry and, like everybody else 5 here, we're also disappointed that this unexpected 6 development last week will lead to an inevitable delay 7 in the Inquiry proceeding. That is going to cause some 8 effect in terms of scheduling witnesses, for example, 9 and many of those witnesses, as you know, have to travel 10 from England. There will be a knock-on effect in that regard, but that's something that we'll have to deal 11 12 with.

13 THE CHAIRMAN: I know that you will help us as best you can with that. On no front is this delay going to be 14 15 anything but difficult, and we'll need as much 16 co-operation as we can, both from DLS and the trusts and the individuals to get back on the best possible 17 schedule, whenever that time comes with the witnesses. 18 MR LAVERY: Yes. You can rest assured that the Directorate 19 20 of Legal Services will endeavour to provide the fullest 21 of co-operation in that regard.

22 THE CHAIRMAN: Thank you.

23 MR LAVERY: Could I just say, Mr Chairman, that the delay 24 obviously has taken its toll on the family, but it's 25 also taken its toll on the clinicians and nursing staff,

and they've had this hanging over them as well. I think 1 2 I made that point at a previous hearing. THE CHAIRMAN: I accept that, that if somebody's facing 3 4 criticism, he or she will want to face up to that and give their best possible response to that sooner rather 5 6 than later. I don't suggest the upset is all on one 7 side. MR LAVERY: Just finally, Mr Chairman, could I use this 8 9 opportunity to extend the condolences of the trust on 10 behalf of all of the staff, the trust and the clinicians and to the families of all of the children? Thank you. 11 12 THE CHAIRMAN: And you have no specific points to make about 13 what we're discussing for Wednesday and so on? 14 MR LAVERY: I think it's inevitable, Mr Chairman, that 15 there's no way round that at this stage. It's 16 a development we'll have to deal with. THE CHAIRMAN: Mr Shaw? Before I come back to Mr Millar to 17 18 resume our exchanges, is there any other representative of an individual doctor or nurse or any other person who 19 20 wants to make a point? Miss Linton? 21 MISS LINTON: Leigh Linton. I am representing Dr Armour. 22 Just to add to what Mr Lavery has just said --23 undoubtedly, as you'll be aware, we came in to the Inquiry on behalf of Dr Armour at a very late stage and 24 had shoehorned counsel in and around other diary 25

commitments. I think it would be helpful if, after next 1 2 week's meeting, we hopefully will have a clearer idea of the degree of delay that's likely to be caused and 3 4 I think, at that stage, when we're aware of when to 5 resume, if we could get timetabling for witnesses sorted 6 out as quickly as possible, because I think for both 7 sides that will help people co-operate with the Inquiry 8 to get things into diaries because I know, for example, 9 that my client does have a number of significant 10 criminal trial commitments, particularly in March and April. 11 12 THE CHAIRMAN: I think she's due to be a witness in criminal 13 trials in England. 14 MISS LINTON: That's correct. So she's very keen to assist 15 the Inquiry and we have, in fact, identified a number of 16 spare days she does have. However, by the very nature of her work, those days are likely to fill up quickly, 17 so we would be keen to get something into the diary for 18 her as soon as possible. 19 20 THE CHAIRMAN: I take that. Thank you very much. 21 MR UBEROI: Good afternoon, if I may add on behalf of 22 Dr Taylor, we are happy to reconvene next Thursday and take the matter on from there. 23 SPEAKER: On behalf of Dr Terence Montague, we're happy to 24 25 convene next Thursday and take the matter from there.

THE CHAIRMAN: He's based in Dublin now; is that right? 1 2 SPEAKER: That is correct, he is based in Dublin, but he is 3 happy to travel up when necessary. 4 MR BROWN: Stephen Brown. We are happy to convene next 5 Thursday. We would add that if we could have an audio 6 recording, that would be clearly preferable. 7 THE CHAIRMAN: I agree. Thank you very much. Mr Millar? 8 9 MR MILLAR: We're very keen on the recording idea. The only 10 other point I would raise just for thought is this. We are all familiar now with meetings between experts in 11 12 various contexts, clinical negligence claims and, no 13 doubt, criminal trials. What we're not so familiar with is expert meetings attended by lawyers. I wondered to 14 15 what extent that's something that you have given 16 consideration to. I think the proposal is that the meeting will be led by Inquiry counsel. 17 THE CHAIRMAN: Yes. 18 MR MILLAR: I don't take any exception to that. But it's 19 20 certainly an unusual feature for any lawyers to be 21 present. Normally what one does is one produces an 22 agenda with perhaps focused questions of the kind that 23 have been suggested and let the experts get on with it. If they're going to be recorded, they're recorded. More 24 usually, there would be a minute of their meeting with 25

points of agreement and points of disagreement. It is unusual, sir, to have lawyers involved. I appreciate that counsel to the Inquiry is in a unique position --THE CHAIRMAN: -- because she doesn't have a line to push, whereas lawyers are typically excluded from meetings because they do have a line to push.

7 MR MILLAR: Exactly. I think there are two factors. One is 8 excluding people who might have a line to push, but also 9 sometimes lawyers, even neutral lawyers being present, 10 might have an inhibiting effect on the type of discussion that the medical experts might have. 11 In 12 order for a relatively simple discussion for them to be 13 comprehensible to us, that can have quite an impact on 14 the nature of the dialogue whereas if they're allowed to 15 get on with it, they can probably cover a lot more 16 ground more quickly and hopefully reduce things to a form which can be communicated to a lay Inquiry. 17 18 THE CHAIRMAN: In what I think are the unique circumstances 19 here, I think I do want Ms Anyadike-Danes to be there. 20 You'll be able, if you have any complaints about the way 21 she behaves, you'll be able to pick it up from the 22 minute or the transcript.

23 MR MILLAR: It is an unusual feature.

24 THE CHAIRMAN: I understand. Okay, thank you very much.

25 I think there is a reluctant and unhappy consensus

that we do not start the oral evidence next week, that we have opened the Inquiry today and that we will have a meeting. I will confirm for you who's going to be there physically, who's going to be there by phone link and how the meeting will be recorded. We'll get back to you on that.

7 If I could follow up on Mr Topolski's point. If 8 anybody has a specific issue which they want the experts 9 to address, could they let us have it by, let's say, 10 2 o'clock tomorrow? I'm not necessarily asking for long lists because I think the Inquiry team is at least as on 11 12 top of this hearing as any other team here, but if 13 you have any particular points which you want to be 14 raised with the experts, please let us have them. I'm 15 not guaranteeing every point will be raised, but it will 16 help us shape an agenda or formatting of the meeting.

I think really that, subject to that, that brings an 17 end to today's proceedings. We will certainly make 18 available every additional document which we have for 19 20 you by close of business on Monday and we will then 21 reconvene next Thursday. If I have any clear idea about 22 how I see the way forward, I will circulate that to you 23 on either Tuesday evening next or Wednesday morning. Wednesday by noon so that you have an idea of where we 24 think the Inquiry might be going and when. 25

1	In the meantime, thank you all very much for coming.					
2	I'm glad that at least in some way we have started the					
3	Inquiry today, and I repeat what I said to Mr Quinn					
4	a few minutes ago: I wanted the Inquiry to get off to					
5	the smoothest possible start. We have been tripped up					
6	slightly already. This Inquiry will finish in November					
7	and between now and then we will hear all the evidence					
8	that we have to hear, let everybody say that they have					
9	to say and then I will do a report to the minister.					
10	Thank you very much.					
11	(3.10 pm)					
12	(The hearing adjourned until Thursday 1st March 2012)					
13						
14						
15						
16						
17						
18						
19						
20						
21						
22						
23						
24						
25						

1			INDEX
2			
3			ANYADIKE-DANES1
4	Opening	by MR	McBRIEN120
5	Opening	by MR	TOPOLSKI125
6	Opening	by MR	SHAW128
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			